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ABSTRACT
Zugravu, Monica Viorica. MS. The University of Memphis. May 2012.
Design and Biophysicochemical Properties of Chitosan-Collagen-Calcium Phosphate
Microparticles and Scaffolds for Bone Tissue Regeneration. Major Professor: Joel D.
Bumgardner, Ph.D.
Due to limitations of bone autografts and allografts there is much research
directed at designing synthetic bone grafts. In this work, collagen-chitosan-calcium
phosphate microparticles and microparticle-based scaffolds were compared to their
counterparts without collagen in terms of degradation, cytocompatibility (porosity and
stiffness only for scaffolds). Microparticles exhibited 20% decrease in mass over 6 weeks
and provided an optimal environment for 3-5 fold cell proliferation over 7 days-culture
period. Although there was no effect of collagen addition to microparticles, all the
formulations may be suitable as bone tissue fillers. Further, there was no difference
between control and collagen scaffolds. In general, scaffolds exhibited 23% porosity, 0.61.2 MPa Young’s modulus, 10-25% degradation over 4 weeks, and supported a 4-7-fold
increase in osteoblast cell number over 7 days in culture. While there is room to improve
Young’s modulus of the scaffolds, they are satisfactory bone graft substitutes.
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CHAPTER 1: INTRODUCTION

1.1 Clinical problem statement
Over 1,500,000 bone graft operations are performed every year in the United
States for the treatment of musculoskeletal injuries/diseases including bone fractures,
painful vertebrae, missing teeth, trauma (e.g., craniofacial trauma), osteosarcoma and
birth defects. 1-3 The gold standard for bone graft therapies is the patient’s own bone,
which is called an autograft. Autografts are considered the “gold standard” by many
surgeons because they exhibit osteoconductive, osteogenic and osteoinductive properties
due to resident growth factors.1,4-6 However, an autograft involves a secondary surgery
with donor site morbidity or pain and increased surgical time.7 Allografts are bone grafts
which come from cadavers and, while they have osteoconductive properties, they have
limited osteoinductive properties and availability.1 There is a need to develop synthetic
bone graft materials for bone regeneration.
Some of the synthetic bone graft substitutes are calcium-phosphate ceramicbased. The advantages of these ceramics are: similarity to the mineral phase of bone—
making them osteoconductive—their ability to form direct bonds with the surrounding
bone and minimal immunological and foreign body reactions.8 The disadvantages of
ceramics are: lack of osteoinductivity,8 brittleness and the difficulty to machine into
complex shapes and porous constructs.9 While there has been much research and
development with these materials, their clinical efficacy has been questioned based on the
small sample size, lack of control or comparison groups in most studies and the absence
of a formal assessment of clinical outcomes.9
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Other synthetic bone graft substitutes are polymer-based: natural or synthetic.
On one hand, naturally derived polymers, such as alginate, chitin, chitosan, hyaluronic
acid, collagen etc. are known to support cell attachment, but have poor mechanical
strength.10 On the other hand, synthetic polymers, such as poly(lactic acid), poly(glycolic
acid), poly(lactide-co-glycolic acid), poly-hydroxyl-butarate, poly(ε-caprolactone) have
relatively good mechanical strength (however, in the porous form required for a bone
graft, their Young’s modulus is below the 10 MPa inferior limit of cancellous bone, e.g.
PCL scaffolds11), tunable degradation rates and can be manipulated into desired shapes,
but may have undesirable acidic degradation products, which may stimulate an
inflammatory reaction.12,13
Synthetic bone grafts can incorporate bone morphogenetic proteins (BMPs),
which are growth factors belonging to the transforming growth factor beta superfamily.14
BMPs (e.g., BMP-2 and BMP-7) can be added to osteoconductive graft materials like
calcium phosphates and polymers to make them osteoinductive. BMP-2 was used in
various therapeutic interventions such as bone defects, non-union fractures, osteoporosis,
spinal fusion and root canal surgery.14 Recombinant bone morphogenetic osteoinductive
substitutes15 include composite scaffolds like the Infuse® Bone Graft/LT-Cage® Lumbar
Tapered Fusion for the treatment of degenerative disc disease (DDD) in skeletally mature
patients. The Infuse® Bone Graft was approved as an alternative to autogenous bone
grafts for sinus augmentations, and for localized alveolar ridge augmentations for defects
associated with extraction sockets.16 The Infuse® Bone Graft consists of a solution of
recombinant human bone morphogenetic protein-2 (rhBMP-2) and an absorbable type I
collagen sponge, which acts as a degradable scaffold for the formation of new bone. The
Ti alloy LT-Cage® Lumbar Tapered Fusion is intended to restore the degenerated disc
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space to its original height. Not all components of the Infuse® system are biodegradable,
as is the case of the LT-Cage® or of the intramedullary nail used together with the
Infuse™ Bone Graft to help heal the fractures of the tibia.9 Some of the contraindications
of Infuse® include: known hypersensitivity to rhBMP-2, bovine Type I collagen or Ti
alloy; placement in the vicinity of a resected or extant tumor in patients who are
skeletally immature, or in patients with an active infection at the operative site.17 Along
the same lines, the safety and effectiveness of this device during pregnancy or nursing
has not been established.17
In 2008 the FDA issued a Public Health Notification regarding life-threatening
complications associated with rhBMP when used in the cervical spine.18 There have been
several reports of complications, occurring between 2 and 14 days post-op, such as
swelling of neck and throat tissue, resulting in compression of the airway and/or
neurological structures in the neck; difficulty swallowing, breathing or speaking; and
severe dysphagia following cervical spine fusion with rhBMP due to the anatomical
proximity of the cervical spine to airway structures in the body. Safety and effectiveness
of rhBMP in the cervical spine have not been demonstrated and rhBMP is not approved
by FDA for this use.19
Additionally, osteoinductive growth factors like BMP-2 are expensive (50 µg
BMP-2 are $955, while 10 µg BMP-7 are $40020), are subject to a limited shelf life,21
may have adverse effects like antibody formation and immunological reactions,
especially in cervical spine surgery when the margin for error is minimal.22 Incorrect
placement of the BMP-carrier can induce undesired ectopic bone formation in
surrounding tissues (muscles, nerves, blood vessels).23
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Another strategy to make bone graft materials osteoinductive is to add
mesenchymal stem cells. Cell-based bone graft substitutes include Osteocel Plus,
marketed by ACE Surgical Supply, Inc. It has been investigated for various procedures,
such as spinal fusion and for intervertebral disc regeneration.15 The product contains
living bone cells, including mesenchymal stem cells. It also contains a polymer scaffold,
which helps to enhance and encourage bone growth.15 Currently, clinical studies for
Osteocel Plus are ongoing.24 Safety and efficacy have not been established for cell-based
bone graft substitutes.9
While there are several bone graft substitutes available clinically, they are not
optimal for healing and/or regenerating bone because of the high cost of using growth
factors, high dosing of growth factors, low mechanical properties which require an
external fixation device and unestablished safety and efficacy.3 While some of the
characteristics of ideal bone grafts have been met: cytocompatibility, osteoinductivity,
moldability, peripheric vascularization, handling in the operating room, degradability,
there is still room for improvement. A good vascular supply is imperative for the
successful integration of a bone graft. Histological analysis of bone grafts demonstrates
only 2-3 mm of vascular invasion into the material.25 To increase and maintain the
vascular supply and to avoid necrosis at the core26, a blood vessel may be implanted or
vascular channels and necessary growth factors may be incorporated into the scaffold.25
Two characteristics to consider when evaluating bone grafts are stiffness and
degradation. Although both are desired, stiffness is inversely proportional to degradation
or polymer chain scission27 below the glass transition temperature of chitosan28, so the
right balance has to be achieved. Some bone grafts have the Young’s modulus of cortical
bone, but show low degradation in vitro after six weeks (12%) and in vivo after one
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month.29 Other bone grafts may have compressive strength close to that of bone, but
biocompatibility has not been assessed.30 Further, other bone grafts may even replace
cancellous bone due to Young’s modulus at lower limit for cancellous bone, but are
brittle,31 while other bone grafts have Young’s modulus too high even for cortical bone
replacement and are brittle.32
Chitosan, a polysaccharide from the exoskeleton of crustaceans, is one of the promising
bone graft biomaterials due to its attractive properties: osteoconductivity, biocompatibility,
non-toxic and non-acidic degradation products.33-39 Chitosan also promotes wound
healing, is mucoadhesive, antibacterial and moldable into three-dimensional (3D)
scaffolds, can deliver antibiotics and bone morphogenetic proteins (in case the latter
become cheaper in the future for treatment of a larger population).

33-39

To address the limits of autografts and allografts, our research group had
previously developed composite co-precipitated chitosan/nanohydroxyapatite
microsphere-based scaffolds as bone graft substitutes, which may also be used to deliver
drugs locally.40-42 The 3-D scaffolds mimic the porous architecture of cancellous bone
and have good biocompatibility with osteoblasts, supporting new bone ingrowth in vitro
and in vivo.40,41 Young’s modulus (9.3±0.8 MPa) approached the values for cancellous
bone (10-2000 MPa).43 The microspheres/microparticles or scaffolds can be loaded with
antibiotics and/or growth factors to enhance osteoconductivity and biocompatibility at
complex fracture sites, such as comminuted fractures and segmental bone defects. 42 One
drawback of these scaffolds is a slow degradation profile,40-42 that can be attributed in
part to the high degree of deacetylation (DDA). The high DDA may limit the bone
ingrowth and reduce the overall bone regeneration.44
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We would like not only to maintain the desirable mechanical, cytocompatible or
osteoconductive characteristics of chitosan-calcium phosphate microsphere-based
scaffolds, but also to increase degradation and tissue ingrowth characteristics of the
scaffold. This was achieved by adding a more degradable polymer to the composite
composition. Collagen is a biocompatible and degradable natural polymer that can be
easily combined with chitosan since both are soluble in dilute acids. Additionally, the
inclusion of collagen will help to mimic the native bone extracellular matrix since
collagen is a major constituent of bone along with the calcium phosphate mineral. We
envision/hypothesize that adding collagen to our chitosan-calcium phosphate composite
will improve degradation of the scaffold material without compromising initial
mechanical properties.
1.2 Hypothesis and objectives
Our goal is to develop a scaffold that maintains mechanical strength during the
first 4 months with increased degradation over time. The 4 months are chosen knowing
that the reparative phase of bone healing takes around 18 weeks.45 Further, we would
like the scaffold to degrade completely within 13 months because the remodeling phase
and maturation of bone takes up to 54 weeks.46 This proposal would allow the native
bone to regenerate and fill the void.
Our research approach is to incorporate collagen in a chitosan-based composite to
make a more biomimetic construct, composed of collagen, chitosan (a natural polymer)
and a mineral, calcium phosphate. Chitosan, which contains glucosamine, mimics the
glycosaminoglycan-components of the extracellular matrix, can actively direct the
behavior of cells to facilitate regeneration of bone, is osteoconductive, biocompatible,
mucoadhesive, antibacterial, moldable into three-dimensional (3D) scaffolds and has non-
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toxic and non-acidic degradation products.33-39 Calcium phosphate mimics the chemical
structure of native bone mineral and provides mechanical strength due to its ceramic
structure. Collagen type I will provide an additional biomimetic component to the
composite because it is the most prevalent protein in the extracellular matrix of bone and
is also biodegradable.47 Collagen concentration was chosen as 25% because this value is
almost constant with age in tibial trabecular bone.48 10% collagen was chosen arbitrarily
as an intermediate concentration between 0 and 25%.
We hypothesize that the incorporation of collagen type I into chitosancalcium phosphate composite microspheres increases the degradation rate of the
chitosan-calcium phosphate microspheres and microsphere-based scaffolds.
Furthermore, we hypothesize that incorporating collagen type I into chitosancalcium phosphate microspheres will increase the compatibility of microspheres
with osteoblasts and fibroblasts and of scaffolds with osteoblasts.
1.2.1

Objectives
To test these hypotheses, the following specific objectives were undertaken:

Objective I
Prepare and characterize composite collagen-chitosan-calcium phosphate
microparticles.
a) Incorporate collagen into chitosan-calcium phosphate microparticles (10
mass% and 25 mass%) via a drip co-precipitation method.
b) Determine the amount of type I collagen within the composite collagenchitosan-calcium phosphate microparticles.
c) Determine the amount of calcium phosphate within the microparticles.
d) Characterize the composite collagen-chitosan-calcium phosphate
8

microparticles for shape using digital microscopy; for crystallinity via x-ray
diffraction spectrometry.
Objective II
Characterize the in vitro degradation profile and cytocompatibility of composite
collagen-chitosan-calcium phosphate microparticles.
a) Determine the percent change in mass of the composite microparticles over
a six week-period in a lysozyme-collagenase solution as compared to plain
chitosan microparticles.
b) Determine the percent cell attachment on the surface of the
composite microparticles as compared to chitosan-calcium phosphate
microspheres.
c) Determine the proliferation of cells on the surface of the composite
microspheres quantitatively as well as qualitatively as compared to
chitosan-calcium phosphate microspheres.
Objective III
Characterize the porosity, and mechanical compressive properties of
composite scaffolds based on fusion of collagen-chitosan-calcium
phosphate microparticles using acetic acid and glycolic acid.
a) Determine the porosity of the scaffolds via Archimedes’ principle.
b) Determine Young’s compressive modulus of the scaffolds via
compression testing of hydrated constructs.
Objective IV
Characterize the in vitro degradation profile and cytocompatibility of composite
collagen-chitosan-calcium phosphate scaffolds.
9

a) Determine the percent change in mass of the composite scaffolds over a
month-period in a lysozyme-collagenase solution as compared to chitosancalcium phosphate scaffolds.
b) Determine the percent cell attachment on the surface of the
composite scaffolds as compared to chitosan-calcium phosphate
scaffolds.
c) Determine the proliferation of cells on the surface of the composite
scaffolds quantitatively, as well as qualitatively, as compared to
chitosan-calcium phosphate scaffolds.
1.2.2

Significance
We propose that the fabrication of composite chitosan-collagen-calcium

phosphate microspheres using a co-precipitation method will result in a bone graft
substitute material that will be effective at healing the bone defect. The incorporation of
collagen would make the composites more compatible (since bone is composed of
collagen) and help increase the degradation rate of chitosan scaffolds without losing
initial mechanical strength or the overall osteoconductivity of the polymer-ceramic
composite. This preliminary research is significant as the results would provide data to
support the potential use of a composite collagen-chitosan-calcium phosphate microparticle system as a tissue filler or part of bone graft material (mimicking cancellous
bone) for bone tissue engineering applications in vivo before starting clinical trials.
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CHAPTER 2: BACKGROUND AND LITERATURE REVIEW
2.1 Brief description of skeleton and bones
Bones are organs of the skeletal system.49 Bone tissue, one of the specialized
connective tissues, is characterized by a mineralized extracellular matrix.50 The
mineralization of the matrix is the reason why bone is an extremely hard tissue that is
capable of providing support and protection to the body.50
2.1.1 Bone classification
Bone can be divided in two major types: cortical and cancellous. Cortical bone
forms the outside of the bone and is a compact and dense layer, while cancellous bone
forms the interior of the bone and consists of trabeculae (thin, anastomosing spicules of
bone tissue), weaved in a sponge-like meshwork.49 The spaces within the meshwork are
continuous and are occupied by marrow and blood vessels in living bone.49 Cancellous
bone is typically found at the core of cuboid bones, such as vertebral bones in the spine,
and at the ends of the long bones, such as the femur or tibia.51
2.1.2 Bone anatomy
The mineral in the extracellular matrix of bone is calcium phosphate, mainly in
the form of hydroxyapatite crystals, Ca10(PO4)6(OH)2.50 Thus, bone provides a storage
site for Ca2+ and PO43-.50 Both can be mobilized from the bone matrix and taken up by the
blood as needed to maintain normal levels.50 At the molecular level, the mineralized
collagen fibrils of bone are made up of strings of alternating collagen molecules and
hydroxyapatite, HA crystals, which appear in stair-step configuration.52 When pressure is
applied to the fibrils, some of the weak bonds between the collagen molecules and HA
crystals break, creating small gaps in the fibrils.52 The gaps spread the pressure over a
broader area and protect other, stronger bonds within the collagen molecule itself, which
11

might break if all the pressure were focused on it.52 The stretching between fibrils lets the
tiny HA crystals shift position in response to the force, rather than shatter, which would
be the likely response of a larger crystal.52 Hydroxyapatite crystals are chalk-like52 and
have 30 nm in length and about 2 nm in thickness.53 Hydroxyapatite significantly
enhances the tensile modulus and strength of bone compared with a tropocollagen
molecule alone.54 The stiffening effect depends on the thickness of the mineral crystal
until a plateau is reached at 2 nm.54
As previously mentioned, bone matrix contains type I collagen (90%) and, in
small amounts, a number of other types of collagen (i.e., types V, III, XI and XIII).50,55
Other proteins that constitute the ground substance of bone are present, such as
proteoglycan molecules (which contain a core protein with various numbers of covalently
attached side chains of glycosaminoglycans), multi-adhesive glycoproteins, bone-specific
vitamin K-dependent proteins, growth factors and cytokines.50 The inorganic part of bone
consists of calcium carbonate, magnesium, sodium, sulfate, potassium, chloride, nitrogen,
fluoride and 20% water.55,56
There are five types of cells. Firstly, osteocytes are cells found within spaces
(lacunae) in the matrix.49 Each osteocyte extends processes to communicate with cell
processes of neighboring osteocytes through gap junctions.49 Bone depends on osteocytes
to maintain viability.49 Secondly, osteoprogenitor cells are cells derived from
mesenchymal stem cells, which give rise to osteoblasts.49 Thirdly, osteoblasts are cells
that secrete the extracellular matrix of bone.49 Once the cell is surrounded by its secreted
matrix, it is called osteocyte. Fourthly, bone-lining cells are cells that remain on the bone
surface when no active growth occurs.49 They are derived from those osteoblasts that

12

remain after the bone deposition ceases.49 Fifthly, osteoclasts are phagocytic cells, which
remove bone or are present where the bone has been damaged or is being remodeled.49
Bones are covered by periosteum, a sheath of dense fibrous connective tissue
containing osteoprogenitor cells.49 Bones that articulate with neighboring bones possess
synovial joints covered by hyaline cartilage.49 Bone cavities are lined by the endosteum,
a layer of connective tissue containing osteoprogenitor cells.49 The medullary cavity and
the spaces in spongy bone contain bone marrow.49 Mature compact bone is composed of
cylindrical units called osteons or Haversian canals.49 The osteons are composed of
concentric lamellae of bone matrix surrounding the central, Haversian canal, which
contains the vascular and the nerve supply of the osteon.49 Interstitial lamellae are
remnants of previous concentric lamellae between osteons.49 Because of this
organization, mature bone is also called lamellar bone.49 Circumferential lamellae follow
the entire inner and outer surfaces of the shaft of a long bone, appearing much like the
growth rings of a tree.49 Perforating canals (Volkmann’s canals) are channels in lamellar
bone through which blood vessels and nerves travel from the periosteum and endosteum
to reach the Haversian canal, as well as connecting one Haversian canal to another.49 The
blood that nourishes bone moves from the marrow cavity into and through the bone tissue
and out via periosteal veins.49 Thus, the flow to bone tissue is essentially centrifugal.49
2.2 Bone injury and repair
In the US approximately six million bone fractures occur each year.45 Five to ten
percent of all fractures will have insufficient repair.45,57 Worldwide, in 2000 it was
estimated that 9 million new osteoporotic fractures occurred, of which 1.6 million were
at the hip, 1.7 million were at the forearm and 1.4 million were clinical vertebral
fractures.58 The Americas and Europe accounted for 51% of all these fractures, while
13

most of the remainder occurred in the Western Pacific region and Southeast Asia.58
Osteoporosis and consequently, bone fractures take a huge toll: in Europe, the disability
due to osteoporosis is greater than that caused by cancer (with the exception of lung
cancer) and is comparable or greater than that lost to a variety of chronic diseases, such
as rheumatoid arthritis, asthma and high blood pressure related heart disease. 58
Regarding military injuries, the musculoskeletal combat casualty rate for a US
Army Brigade Combat Team during operation Iraqi freedom was 34.2 per 1,000 soldier
combat-years.59 Spine, pelvis, and long bone fractures comprised 55.9% of the total
fractures sustained in combat.59 Open fractures comprised 5.0 per 1,000 combat-years.59
Natural disasters also have a high incidence of orthopaedic trauma. For example,
other than wound debridement, the most commonly performed procedure during the first
three weeks after the 2010 earthquake in Haiti was fixation of long bone fractures, which
constituted approximately one third of all surgical procedures.60
For car accidents orthopaedic trauma, in a defined area of central Sydney from
mid-1991 to mid-1994, 21.5% of all adult car occupants and 49% of pedestrians
sustaining major injury suffered lower extremity long bone fractures.61
For malignancies of the bone reported by the Surveillance, Epidemiology and End
Results (SEER) program areas from 1975 to 1995, the average annual incidence rate was
8.7 per million children younger than 20 years of age, comprising about 6% of childhood
cancer.62 Bone cancer non-unions arise from this population with bone malignancies.
A retrospective study of 120 consecutive patients treated by a single surgeon for
delayed or failed bone healing with a direct current bone stimulator, showed 86.8%
fracture non-unions, 3.3% arthrodesis non-unions, 2.5% osteotomy non-unions, 4.1%
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malunion osteotomy, and 3.3% primary fixation of open fractures with large segmental
bony defects.63
The cases of orthopaedic fractures listed above shows the potential market for
bone grafts. In 2010, it was estimated that 600,000 bone graft procedures are performed
in the United States annually, and roughly 2.2 million procedures are performed
worldwide, which cost approximately $2.5 billion per year.64
A fracture is a break in bone, which, in some cases, results in bleeding at the
fracture site.65 The initial strength of the bone, the magnitude, direction and rate at which
force is applied determine the extent of the fracture.66 Fractures can be caused by sudden,
high impact forces or by low-level cyclic forces. 66 Sudden, high energy forces produce
some of the most severe fractures: comminuted and segmental bone fractures.67-70
Comminuted fractures have more than two fragments, while segmented fractures are the
ones in which the bone fragment is completely separated from non-fractured bone by
fracture lines.70 In closed (simple) fractures in which the skin is not breached, normal
bone healing takes place. Bone healing occurs in three different stages: the early
inflammatory stage (hematoma formation), the repair stage (the fibrocartilaginous and
bony callus formation) and the remodeling stage. 55,57,69,70 When a fracture occurs, not
only is there a discontinuity in the bone, but also in the surrounding vascular system.66 A
hematoma forms at the fracture site and inflammatory cells and fibroblasts migrate to the
fracture site due to prostaglandin and growth factor release.66 Next, granulation tissue is
formed, vascular ingrowth is initiated and mesenchymal cells begin to migrate to the
fracture site.55,57,70 In the repair stage, as the blood supply to the fracture area improves,
osteoblasts secrete osteoid and a collagen matrix is formed.66 Four to six weeks after the
initial fracture the periosteum undergoes intramembraneous ossification and a
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fibrocartilaginous, soft external callus is formed. The internal osteoid mineralizes and the
internal callus develops into woven bone. In the last stage of bone healing, the woven
bone is replaced by cortical bone and the bone is restored to its original shape and
strength.55,57 Bone remodeling can last for months to years and occurs where forces
require it, as stated by Wolff’s law. 55
In large comminuted or open compound fractures, the vascular supply to the bone
tissue may be completely destroyed. Segmental and comminuted fractures are at
increased risk for the development of non-unions (no development between bone
fragments) and for becoming infected and developing osteomyelitis.67-71 These two types
of fractures are so discomforting because the blood supply to the fracture area is
destroyed and necrosis of the bone can occur. These fractures can be caused by war
injuries, motor vehicle accidents, gunshot wounds and crush injuries. 67,68 Normal bone
healing does not occur in large fractures/injuries where the vasculature is destroyed. To
treat these situations, bone grafts are used to fill in the gap and to help heal the bone in
order to maintain normal geometry and size of the bone.
The ability of bone to repair itself is lost in a critical size defect. Factors that
cause critical size defects include non-unions, bone cancer and birth defects. The
critical size bone defect in humans is not clearly defined, but usually a defect > 1cm
is considered to be a critical-sized defect.72 The length of segmental bone defects
ranges from 0.4 to 7.6 cm and depends on the anatomical location of the defect.73
Usually, the treatment of critical size bone defects involves bone graft implantation in
conjunction with internal fixation in addition to long-lasting therapies to restore bone
continuity and stability.74,75
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2.3

Bone grafts
Current treatment options for non-unions and bone defects include: autografts,

allografts and synthetic bone grafts.
2.3.1 Autografts are bone grafts which come from the patient’s body. Considered
the “gold standard” by many surgeons, it has very good osteoconductivity and also great
osteoinductivity due to its high content of resident growth factors.6 The disadvantages
are: the higher morbidity of the donor site, the secondary surgical access in a remote
location of the body in order to harvest the bone (hip, for larger quantities, chin or the
back of the jaw).6 Autogenous bone grafts have shown to be some of the most
predictable grafts in surgery6 and are highly dependent on the quality of the patient’s
bone.
2.3.2 Allografts are a close relative of the autograft, in that they are of human
origin, usually from cadavers from a bone bank.6 Despite the lack of a secondary surgery
for harvest and the osteoconductive properties, allografts have very little if any
osteoinductive properties because they lack bone cells and exposed osteoinductive
proteins.6 Thus, graft assimilation and maturation takes longer than with the autografts.6
2.3.3 Synthetic bone grafts
Due to the disadvantages of autografts and allografts, scientists have looked for
alternatives with quicker recovery times, lower costs and reduced risks, such as synthetic
bone grafts. In these, scientists have tried to tailor biophysical properties so that an ideal
scaffold can result.
In case bone fails to unite over a defect, a bone graft offers a framework on which
cells can attach and proliferate.76 The sine qua non for success of bone grafts includes:
1. Interconnective pores to promote osseointegration and vascularization77

17

2. Controlled biodegradability so that the tissue will eventually replace the
scaffold
3. Adequate surface chemistry to favor cell attachment, proliferation and
differentiation
4. Appropriate mechanical properties to match the intended site of implantation
and handling
5. No serious adverse effects
6. Easy manufacture and sterilization
7. Easy handling in the operating room45,76
Porosity, as a physical parameter, should provide adequate space for cell
migration and expansion and maintain the transport of nutrients and waste products.78
Various percentages exist for 3D scaffold fabrication, with porosities ranging from 10 to
97%.79 However, increasing the porosity decreases mechanical strength, so a balance has
to be achieved between porosity and mechanical stability.80 Scaffold pores ought to be at
least 50 µm to promote osteogenesis.66
A scaffold ought to maintain mechanical strength during the first 4 months with
increased degradation over time because the reparative phase of bone healing takes
around 18 weeks.45 Further, the scaffold ought to degrade completely within 13 months
because the remodeling phase and maturation of bone takes up to 54 weeks.46 This would
allow the native bone to regenerate and fill the void.
Cells respond to the chemistry, topography and surface energy of the substrates
with which they interact.45 The material substrates should have molecules of the
extracellular matrix and initiate the attachment of proteins of the right type, amount and
conformation, which modulate cell functions.81 It was shown that hydrophobic
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biomaterials promote the adsorption and retention of proteins like fibronectin and
fibrinogen.82 Moreover, calcium-based ceramics dissolve and precipitate on their surface,
forming a carbonate-containing hydroxyapatite layer, which is osteoconductive.83
Scaffolds should have no adverse side effects like immunogenicity, cytotoxicity
and tumorigenicity. 45 Scaffolds should be easy to manufacture and sterilize (without
compromising properties) for mass production. Bone grafts should be easy to handle in
the operating room, without preparatory procedures so that infections would be
minimized.
2.3.3.1 Ceramics
Ceramic-based bone grafts include calcium phosphate, calcium sulfate, and
bioglass, which can be used alone or in combination with other materials.
Most of the ceramic-based bone graft substitutes currently available are calcium
phosphates.15 Several types of calcium phosphates exist: tricalcium phosphate, synthetic
hydroxyapatite, and coralline hydroxyapatite, and are available in pastes, putties, solid
matrices, and granules.15 Such calcium phosphate products include Bio-Oss (Osteohealth,
Inc, Shirley, New York) and OsteoGraf.15 Bio-Oss uses hydroxyapatite as a particulate
while OsteoGraf uses HA as blocks and particulates.15 Vitoss (Orthovita, Inc) is a
tricalcium phosphate available in the form of a solid piece, putties or pastes.15 ProOsteon
is a unique product based on sea coral, which contains HA and is similar in structure to
trabecular bone. Nevertheless, like many of the solid calcium phosphates, ProOsteon is
brittle and not suitable for use in load-bearing sites.15
Vitoss® Scaffold Synthetic Cancellous is a non-load bearing calcium phosphatebased Bone Void Filler (Orthovita Inc.) indicated for use in the treatment of surgically
created osseous defects or osseous defects resulting from traumatic injury to the bone
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(i.e., the extremities, spine, and pelvis).9 It can be administrated using a prefilled syringe.9
The surgeon can use either a secondary syringe or the vacuum line to aspirate blood or
marrow into the Vitoss-Filled Cartridge.9 Bone void fillers similar to Vitoss include
Biosorb® Resorbable Bone Filler (Science for Biomaterials) and chronOS™ (SynthesStratec Inc.), although they are less porous.9 Similar to other β-TCP, Cross Bone is a
resorbable, biphasic ceramic implant composed of 60% hydroxyapatite and 40% β-TCP
in the form of granules used for bone reconstruction.9 Examples of calcium phosphatebased bone grafts include: Actifuse (a silicate-substituted calcium phosphate),
BoneSource, BoneSave, HydroSet (Stryker, Kalamazoo, Missouri), and OsSatura TCP
from Integra Orthobiologics, Plainesboro, New Jersey (pure β-TCP; it forms a welldefined interconnected porosity that provides a high level of osteoconductivity). 15
Calcium phosphates are easily handled as putties or pastes, but do not have
appropriate mechanical properties for load-bearing sites because they are brittle at high
Young’s modulus (in the case of hydroxyapatite). One more important issue with calcium
phosphates is that they can possess a slow degradation rate, which may vary from months
to years or it might even be incomplete.84
Calcium sulfate, also known as plaster of Paris, is biocompatible, bioactive, and
resorbable after 30-60 days.15 Because of its rapid degradation it also rapidly loses its
mechanical properties.15 Hence, it is a questionable choice for load-bearing
applications.15 Calcium-sulfate bone grafts include: Osteoset, a tablet for use for defect
packing which is degraded in approximately 60 days (Wright Medical technology, Inc.)
and AlloMatrix, which is Osteoset combined with demineralized bone matrix, DBM. The
latter is sold as a putty or an injectable paste.15 However, a 13.8%-19.0% incidence of
self-limited and benign adverse reaction was reported to OsteoSet bone graft substitute, a
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surgical grade calcium sulfate in a pure, uniform, crystalline form (Wright Medical)85,
which spurs the quest for new materials or material combinations for bone grafts. As
there is no known cell-mediated regulatory connection between the degradation of
calcium sulfate cements and the new bone formation, there is a risk that degradation
might be too rapid, causing a new space if bone formation is not fast enough.86
Bioactive glass (in particular, bioglass) is a biologically active silicate-based
glass.15 Its applications are limited by high modulus and brittle, but it has been used in
combination with polymethylmethacrylate to form bioactive bone cement. It has also
been used as a coating on metal implants in the form a calcium-deficient carbonated
calcium phosphate layer, which facilitates the chemical bonding of the implant to
surrounding bone. Products from bioglass include Biogran (developed by Orthovita and
licensed to Biomet 3i, Implant Innovations, Inc, Palm Beach Gardens, Florida) and
Novabone (NovaBone Products, LLC, Alachua, Florida).
In conclusion, the advantages of ceramics for bone grafts are: similarity to the
mineral phase of bone—making them osteoconductive—their ability to form direct bonds
with the surrounding bone, biocompatibility and minimal immunological and foreign
body reactions due to the lack of proteins associated with them.8 The disadvantages of
ceramics are: lack of osteoinductivity,8 brittleness, the difficulty to machine into complex
shapes and porous constructs, and low degradation for the ceramics with Young’s
modulus close to that of cancellous29 or cortical bone.87
2.3.3.2

Polymers

Polymers used as bone graft substitutes for bone tissue engineering
applications can be either derived from natural sources: polysaccharides such as
alginate, chitin, chitosan and hyaluronic acid, or proteins such as soy, collagen, fibrin
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and silk--or from synthetic sources: poly(lactic acid), poly(glycolic acid), poly(lactideco-glycolide), poly(ε-caprolactone) and polyhydroxybutyrate.10,88,89 On one hand,
naturally derived polymers are known to support cell attachment but have poor
mechanical strength.10 On the other hand, synthetic polymers have relatively good
mechanical strength (however, in the porous form required for a bone graft, their
Young’s modulus is below the 10 MPa inferior limit of cancellous bone, e.g. PCL
scaffolds11), tunable degradation rates and can be manipulated into desired shapes, but
may have undesirable acidic degradation products, which may stimulate an
inflammatory reaction.12,13 Examples include: Cortoss (Orthovita, Inc, Malvern, PA),
made of bis-glycidyl methacrylate; Open Porosity Poly(lactic Acid) polymer, OPLA,
(TMH Biomedical, Inc., Duluth, MN), made of a PLA/PGA copolymer; Immix
(Osteobiologics, Smith and Nephew, Memphis, Tennessee), made of a PLA/PGA
copolymer as the base material and PGA fibers, Bioglass (a 45S5-type glass), and
calcium sulfate as additives to vary stiffness; and Healos (Depuy Orthopaedics Inc,
Warsaw, Indiana), an osteoconductive matrix made of cross-linked collagen fibers that
are fully coated with HA through a proprietary 360 accretion process).15 Lastly, Ahn et
al. produced highly porous and surface-roughened/layer-by-layer 3D poly(εcaprolactone) scaffolds with thickness of more than 2 mm with high osteoblast-like
MG63 cell viability, increased ALP activity and calcium mineral.90 One of their
limitations is the stable size control of micro/nanosized electrohydrodynamic directprinted struts.90
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2.3.3.3 Composites
Composite systems maximize the advantages of two or more materials, while
minimizing their individual disadvantages. Three examples of bone void fillers available
on the market are provided:
1. Healos (DePuy Orthopaedics, Inc, Warsaw, Ind) is a polymer-ceramic
composite consisting of collagen fibers coated with hydroxyapatite and
indicated for spinal fusions,15 which is osteoconductive and stronger than
collagen alone due to addition of hydroxyapatite, a crystalline form of
calcium phosphate. However, neither does it bear loads, nor does it have a
dual structure to mimic the cortical and cancellous lamellar composition of
bone. All available bone graft materials are limited in the latter regard: they
do not mimic the 3D bone architecture of bone. Using solely a cancellous
bone replacement consists in the use of external fixation devices, which have
to be removed surgically, while cortical bone replacements used as a standalone may cause stress-shielding.
2. The Vitoss® Scaffold Foam™ (Orthovita Inc., Malvern, PA), a bone void
filler, consists of a mixture of β-tricalcium phosphate, β-TCP, and Type I
bovine collagen in a hydroxyapatite carrier.9 Used alone, this product does not
have osteoinductive properties, and, since most if it is made of β-TCP, it is
brittle. 91
3. Integra MOZAIK™ Osteoconductive Scaffold (Integra LifeSciences
Plainsboro Township, NJ ) is made of 80% tricalcium phosphate and 20%
type I collagen; it resorbs at a rate consistent with the formation of new
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bone15. Similarly, this product does not have osteoinductive properties, and,
since most of it is made of β-TCP, it is brittle.
Several research labs are investigating alternative bone grafts: Chen et al.
developed a PLLA scaffold with apatite/collagen composite coating.92 PLLA scaffolds
with apatite/collagen coating exhibited better Saos-2 cell viability than uncoated PLLA
scaffolds or PLLA scaffolds with hydroxyapatite coating92. Similarly, Kim et al.
produced porous poly(D,L-lactic-co-glycolic acid)/nanohydroxyapatite (PLGA/ HA)
composite scaffolds, coated with HA in simulated body fluid, SBF. The PLGA/HA
scaffolds exhibited higher osteoblast cell growth, alkaline phosphatase activity and
mineralization than PLGA scaffolds93. Ciapetti et al. found that the HA-added poly(εcaprolactone)-based polymers obtained the best colonization by Saos-2 cells after 3-4
weeks and that more mineral was formed on HA-added poly(caprolactone)-based
polymers coated in simulated body fluid, SBF than on PCL-based polymers.94 Lickorish
et al. found that a porous, collagenous scaffold, biomimetically coated with
hydroxyapatite using SBF, supported L-929 fibroblasts and rabbit periosteal cellular
attachment and proliferation (it is assumed that the scaffold is weak because the
majority of the scaffold is comprised of collagen).95 MG63 osteoblasts attached to
collagen-derived gelatin/hydroxyapatite (HA) nanocomposites to a significantly higher
degree and subsequently proliferated more than those conventionally mixed gelatin-HA
composites.96 The nanocomposite scaffolds retained less-crystallized and smaller-sized
apatite crystals (~40 nm) and a more developed pore configuration than the
conventional ones.96 Collagen beads can be formed by extruding collagen solution into
chondroitin sulfate A solution.97 Subsequently, the collagen beads thus formed are
soaked in SBF solution to form nanohydroxyapatite on the surface and mimic the
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formation process of natural bone matrix, providing a substrate for cell growth and
enhancing the osteoblast-like cell differentiation of MG63 cells.97 Further, MC3T3E1cells proliferated on poly-L-lactic acid (PLLA), chitosan and hydroxyapatite (HA)
microsphere-based scaffolds (macroporosity >50%) and formed an extracellular matrix
network, while differentiating into mature osteoblasts, as indicated by alkaline
phosphatase activity.98 While no degradation was assessed, Young’s modulus of 0.42
MPa indicated their use in non-load bearing applications.98 In spite of the promising cell
growth (osteoblasts, in particular) and even increased ALP activity and mineralization in
some cases, the mechanical properties constitute an issue that needs to be addressed so
that the scaffolds may become load-bearing.
Recently, a calcium phosphate/polyurethane with both HA and β-TCP
composites was developed for weight-bearing implants.29 Although it reached high
compressive modulus values which ranged from 2.5 to 3.6 GPa, this potential bone graft
cannot be used to replace cancellous bone and may cause stress shielding. Although the
clonal osteoblastic cell line, 2T3, isolated from murine calvaria shows the
biocompatibility of the implants, both the in vitro (12% degradation after 6 weeks) and
in vivo degradation in a rat model are low.29 The problem with the low degradation rate
is that the bone defect is not completely healed, since the partly degraded scaffold-new
bone combination may not be as stiff and cohesive as native bone itself.
Chitosan, a natural-based nontoxic, biocompatible, and biodegradable polymer
with anti-microbial activity, is also reported to promote osteogenic progenitor cell
recruitment and attachment, facilitating bone formation.38,99 Chitosan and its derivatives
are believed to accelerate wound healing by enhancing the functions of inflammatory
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cells and repairing cells.38 Recent studies further indicated that chitosan and its
derivatives also are novel scaffold materials for tissue engineering and gene delivery.38
One property of chitosan that must be taken into account when designing
chitosan biomaterials is the degree of deacetylation (DDA). Chitin has no DDA or 0%
DDA, while pure chitosan has 100% DDA.66 Chitosan materials with DDA close to
50% are the most degradable in vitro and in vivo.33,38,100 Below or above 50% DDA,
chitosan loses degradability due to the fact that its chains pack more closely together,
giving it a more crystalline character.66 Chitosan with DDA>95% has been known to
last for months. 33,38,100
Chitosan has been modified or combined with other materials in bone
regeneration. For example, lyophilized N,N-dicarboxymethyl chitosan-calcium
phosphate sponges quicken bone wound healing in femurs of sheep and in humans
undergoing apicectomies and dental avulsions.101 However, the surgical defect in sheep
was filled with a tissue without the histoarchitectural characteristic of bone tissue and
the dental defect was weakly load-bearing, so the bone graft is non-load-bearing.101
Hydroxyapatite-chitin lyophilized gels were loaded with MSC-induced osteoblasts were
reported to be osteoinductive and exhibited neovascularization and rapid degradation
after 3 months in vivo compared to the chitin control.102 The imidazole-linked chitosan
material promoted mineralization, induced bone formation and filled critical size bone
defects with the apposition of trabecular bone in the femoral condyle of sheep.103
Chitosan/tricalcium phosphate sponges incorporating platelet-derived growth factor
(PDGF) induced new bone formation in a rat calvarial defect.104 Chitosan-alginate
gel/mesenchymal stem cells/bone morphogenetic protein-2 composites were found to
stimulate new bone formation when injected into a mouse.105 Even though most of these
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chitosan gels and sponges stimulate bone formation, they still lack stiffness needed for
load-bearing applications or the quality of the bone produced is poor (i.e. cancellous
bone on the outside with a central mineralization nodule in association with a fibrous
component).103
Other groups are also struggling with degradation of chitosan scaffolds: 3Dbioplotted, cell-seeded tricalciumphosphate/chitosan/collagen and tricalciumphosphate
/collagen scaffolds increased the amount of newly formed bone within ovine critical-size
calvarial defects, but stiffness and biodegradation of materials are not appropriate for the
application in cranio-facial surgery and have to be improved.106
When compared to plain chitosan scaffolds, composite chitosan-hydroxapatite
scaffolds exhibited rougher surface and greater surface area for cell attachment, about 3x
higher Young’s modulus and increased pre-osteoblast proliferation.107 The chitosancrystalline calcium phosphate scaffolds were tougher and more flexible than what has
been reported for pure calcium phosphate scaffolds.107
Several researchers have investigated chitosan,108-111 and chitosan composites
with calcium phosphate,40,112-114 beta-tricalcium phosphate (β-TCP) and gelatin
crosslinked with glutaraldehyde,115 collagen , 116 hydroxyapatite,117-119 but the
shortcoming of the materials is that their Young’s modulus was below that of cancellous
bone. For collagen-based implants reinforced by chitin fibers values for mechanical
strength were not reported, which may be low due to the collagen base material.120
Macroporous HA/β-TCP nesting chitosan sponges exhibited higher Young’s modulus of
15 MPa, but they are brittle due to high percentage of ceramics.31 Further, it was
reported that Young’s modulus of nanocomposites of chitosan–hydroxyapatite–
polygalacturonan was 23.63 GPa, which is too high even for cortical bone replacement;
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moreover, the composites can be brittle in nature due to HA.32 In another study by Li et
al. 30/70 chitosan/n-HA composite had compressive strength of 119.86 MPa close to
that of bone, but no cell studies were pursued.30 Lastly, cellulose derivatives-based
scaffolds showed Young’s modulus and strength in the mid-range of human trabecular
bone, but had low degradation: mass loss of 10-15% after 6 months.121 All in all, these
studies show the lack of scaffolds with a Young’s modulus close to that of bone, that are
also not brittle, slowly degrading and showing cell viability.
Broadly, composite bone grafts (with or without chitosan) have been shown to
be osteoconductive,15 and osteoinductive when loaded with MSC-induced osteoblasts.102
Composite grafts show high osteoblast,29,90,92,94,96,97 periostal and associated cells
viability,95 increased ALP activity 77, 78, 80 and mineralization,77, 78, 103 exhibit
neovascularization,102 rapid degradation102 and new bone formation in vivo.102,103,105
Their main limitation is that they are non-load-bearing or no mechanical properties are
observed. Some bone grafts have Young’s modulus of cortical bone, but show low
degradation in vitro after six weeks (12%) and in vivo after one month.29 Some bone
grafts may have compressive strength close to that of bone, but no biocompatibility was
assessed.30 Further, some bone grafts have Young’s modulus at the lower limit for
cancellous bone, but are brittle,31 while other bone grafts have Young’s modulus too
high even for cortical bone replacement and are also brittle.32 A summary of bone graft
types together with their advantages and disadvantages is presented in Table 1.

28

Table 1. Characteristics of the classes of bone grafts.
Bone graft type

Pros

Ceramics:
CaP, CaSO4, bioglass

• osteoconductive
• direct bonds with the
surrounding bone
• biocompatibility
• minimal
immunological and
foreign body reactions8

Polymers:
• Natural:
• Polysaccharides:
alginate, chitin,
chitosan and
hyaluronic acid
• Proteins:
soy, collagen,
fibrin and silk

• support cell
attachment

•

Synthetic:
PLA, PGA, PLGA,
PCL and PHB10,88,89

Composites
• calcium
phosphate/polyurethane
with both HA and β-TCP
• collagen fibers coated
with HA
• PLGA/HA scaffolds
• Gelatin/HA
• Collagen beads coated w/
HA
• PLLA/chitosan/HA
scaffolds
• Chitosan/TCP sponges

• relatively good
mechanical strength
• good degradation
rates
• anatomical fit
• osteoconductive15
• osteoinductive when
loaded with MSCinduced osteoblasts102
• high
osteoblast,29,90,93,95-98
fibroblast and periostal
cell viability96
• ALP activity80,82,104
and mineralization80, 82,
106

• neovascularization102
• rapid degradation102
• new bone formation
in vivo40,102,106
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Cons
• lack of
osteoinductivity8
• brittleness
• the difficulty to
machine into complex
shapes and porous
constructs
• low degradation for
the ceramics with
Young’s modulus of
cancellous29/cortical
bone.87
• poor mechanical
strength.10

• undesirable acidic
degradation products,
which may stimulate
an inflammatory
reaction.12,13
• are non-loadbearing
• non-optimized
growth factor loading
• no mechanical
properties are
observed

One strategy to improve tissue engineering scaffolds for bone grafts is through
the use of microspheres. The microspheres when packed together like balls in a box,
provide for complete interconnected porosity for cell/tissue ingrowth. The microspheres
provide a stronger 3D network to improve mechanical loading, and serve as a negative
template for bone formation and organization.122
The ease of packing into various shapes also makes microsphere-based bone
grafts attractive for filling irregular bone defects. Using this approach, Chesnutt et al.
developed a co-precipitation method to form chitosan – calcium phosphate composite
microspheres and then formed scaffolds by fusing the beads.40 The scaffolds were made
with a chitosan with a high degree of deacetylation: 92.3%. The addition of
hydroxyapatite to chitosan increased the surface roughness, the compressive modulus
(by almost 3x), when compared to other chitosan-calcium phosphate composites or
calcium phosphate scaffolds alone. Not only were the scaffolds stronger, but also they
showed better osteoblast proliferation as compared to chitosan scaffolds.40 The Young’s
modulus of these scaffolds, 9.3±0.8 MPa, was at the lower limit for cancellous bone. In
the in vivo rat calvarial defect study, the scaffolds showed good osteoconductivity, but
the in vivo degradation of scaffolds was low, which may have also limited bone tissue
ingrowth.41 Chesnutt showed the potential of chitosan-calcium phosphate microspherebased scaffolds to serve as bone grafts through osteoblast proliferation, Young’s
modulus at the lower range of cancellous bone, good osteoconductivity, but the material
had a limitation: low degradation, attributed in part to the high DDA.41
Consequently, the main focus of this study was to improve the degradation of
these chitosan-calcium phosphate scaffolds, which may be used as cancellous bone
replacement. One way to improve their degradation is to add collagen to the chitosan-
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calcium phosphate composite material. Degradation would increase, in part because
collagen is highly degradable. The biomimetic nature of the composite would also be
increased since collagen is the major ECM protein of bone which may further enhance
its potential to serve as a bone graft substitute material.
Since native bone is composed of mineral, collagen and glycosaminoglycans, the
biomimetic composite scaffold was designed with calcium phosphate mineral, collagen
and chitosan instead of glycosaminoglycans to mimic bone composition. The three
building materials of the microspheres and the rationale for combining all these
biomaterials into bone grafts will be further discussed.
2.4 Chitosan
Chitosan, a partially N-deacetylated derivative of chitin, is a natural linear
polysaccharide derived from the exoskeleton of crustaceans. Chitosan holds promise in
biomedical research due to its attractive properties of osteoconductivity, biocompatibility,
non-toxic and non-acidic degradation products, promotion of healing, mucoadhesiveness,
wound healing properties, moldability into three-dimensional (3D) scaffolds, making it
an ideal candidate for tissue engineering and drug delivery applications.
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Chitosan

exists in various forms: microspheres, films, scaffolds, gels, bioactive coatings for
orthopaedic and craniofacial implants, which support bone cell in-growth and is able to
deliver antibiotics and bone morphogenetic proteins.113 Chitosan sponges fabricated by
freeze-drying,123 chitosan microspheres39 and cross-linked chitosan microspheres 124 were
used in bone regeneration, albeit for non-load-bearing purposes.
In spite of its nontoxic degradation byproducts: saccharides and glucosamines
which are incorporated into glycoproteins or excreted as CO2,33 chitosan’s slow
degradation profile due to the high degree of deacetylation, DDA, can limit the bone
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growth within the scaffold and bone defect volume44, consequently restraining the use of
chitosan as a bone graft for tissue engineering and drug delivery.
The DDA and the molecular weight are two important properties of chitosan and
are known to affect how chitosan will perform clinically. It has been reported that
biodegradation of chitosan increases with the decrease in degree of deacetylation110 (up
to 50% DDA33,38,100) as well as with the decrease in molecular weight of the
polymer.125,126 The decrease in DDA reflects lower crystallinity. Therefore, a lower DDA
and molecular weight chitosan is a way to increase degradation.
It has also been reported that the mechanical strength of chitosan decreases
with the decrease in the degree of deacetylation127,128 and molecular weight of
chitosan.129 Since the scaffolds are aimed at a load-bearing application, the lowest DDA
and molecular weight should not be chosen, which brings up the issue of finding a suitable
low DDA and molecular weight, which will provide some mechanical strength and
increase degradation.
On the one hand, chitosan has immense potential as an orthopaedic biomaterial
41,42,130-134

. On the other, the low degradation rate of chitosan microsphere-based 3D

scaffolds limits its use in tissue engineering and drug delivery applications. To increase
degradation, collagen was added to the microparticles because it undergoes rapid
degradation upon implantation.44 Calcium phosphate, which is osteoconductive, was
added as well to mimic the major component of the inorganic phase of bone.42
2.5 Calcium phosphate
Calcium phosphate is added to the microparticles because it is osteoconductive,
has good strength and hardness.66 Calcium phosphates have been used in implant
coatings, drug delivery systems, bone grafts and other biomedical applications.113,135-139
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The reason for combining bioactive ceramics with degradable polymers, such as
chitosan, is to create scaffolds that maintain the bioactivity and strength of calcium
phosphate.
2.6 Collagen
Collagen is the most widely found protein in mammals (25% of our total protein
mass) and is the major provider of strength to tissue.140 A typical collagen molecule
consists of three intertwined protein chains that form a helical structure.140 These
molecules polymerize together to form collagen fibers of varying length, thickness, and
interweaving pattern (ropelike structures, meshes or networks).140 The predominant form
used in biomaterial applications is type I collagen, which is a "rope-forming" collagen
and can be found almost everywhere in the body, including tendons, the endomysium of
myofibrils and the organic part of bone. 141 The basic unit of the extracellular matrix
consists of mineralized type I collagen fibrils, with collagen comprising about 90% of the
protein.142
Collagen is resorbable, non-toxic and excellent for attachment and biological
interaction with cells.143 Moreover, collagen may be processed into a variety of formats,
including porous sponges, gels, and sheets, and can be cross-linked with chemicals to
make it stronger or to alter its degradation rate. 143 Collagen has been used in many types
of surgery (e.g., plastic surgery), cosmetics, drug delivery, as well as in bioprosthetic
implants and tissue-engineering of multiple organs.143 Collagen has its own
disadvantages though: depending on how it is processed, it can potentially cause
alteration of cell behavior (e.g., changes in growth or movement), have inappropriate
mechanical properties, or undergo contraction (shrinkage).143,144 Because cells interact so
easily with collagen, cells can actually pull and reorganize collagen fibers, causing
scaffolds to lose their shape if they are not properly stabilized by crosslinking or mixing
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with another less "vulnerable" material (chitosan, in our case). Exciting research is being
performed to bind various proteins or growth factors to collagen as signaling molecules
in order to tailor cell behavior to specific applications of interest.143 One may attach
molecules that encourage cells to grow (e.g. bone morphogenetic proteins), to move, to
make new blood vessels, to make a certain protein, or to perform many other actions. The
biocompatibility and high degradation rate of collagen are exploited in this work by
combining collagen with the chitosan.
2.7 Composite chitosan-collagen biomaterials
Initially, chitosan and collagen have been studied as extracellular matrix
components. Tan et al. observed that overall matrix integrity increased with the
proportion of chitosan to collagen.145 The addition of chitosan greatly influences
ultrastructure and changes collagen fiber cross-linking, reinforcing the structure and
increasing pore size.145 Although the proliferation of K562 lymphoblasts was inhibited
with an increasing proportion of chitosan, cell function-based on cytokine-release was
greatly augmented.145 The cell line was inappropriate for bone tissue engineering and the
gels are non-load bearing. Similarly, Wang et al. demonstrated that human bone marrow
stem cells, hBMSC can attach and proliferate in three-dimensional matrices composed of
glyoxal-crosslinked 50/50 chitosan/collagen, and that these hydrogels supported
osteogenic differentiation in response to stimulation.146 Likewise, Wang et al. used betaglycerophosphate (beta-GP), an osteogenic medium supplement and a weak base, to
simultaneously initiate gelation of chitosan-collagen composite materials at physiological
pH and temperature.147 DNA content for adult human bone marrow-derived stem cells
(hBMSC) encapsulated in such hydrogels increased twofold in materials containing
collagen. 147 Collagen-containing materials compacted more strongly and were
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significantly stiffer than pure chitosan gels.147 The presence of chitosan in materials
resulted in higher expression of osterix and bone sialoprotein genes in medium with and
without osteogenic supplements, higher phosphatase activity and calcium deposition in
osteogenic medium.147 Chitosan-collagen composite materials have potential as matrices
for cell encapsulation and delivery, or as in situ gel-forming materials for non-load
bearing bone repair.147
Nitzsche et al. used a suspension-quick-freezing and lyophilization method to
incorporate nanohydroxyapatite into a polymeric matrix consisting of collagen and
chitosan.148 In vitro and in vivo studies need to be carried out.
In order to remineralize dentine affected by caries, Xu et al. modified the surface
of partially demineralized dentine sections, mainly composed of type I collagen, by
covalent immobilization of phosphorylated chitosan, P-chi on the collagen surface.149
The results indicated that the covalent immobilization of P-chi can significantly induce
biomimetic deposition of calcium phosphate.149 No mechanical testing was carried out.
Several chitosan cement formulations were prepared, none of which were loadbearing: Zhao et al. developed a novel human umbilical cord mesenchymal stem cell
(hUCMSC)-encapsulating, fiber-reinforced injectable calcium phosphate cement (CPCF)
scaffold, which incorporated calcium phosphate powders, chitosan, and absorbable
fibers.150 The results indicated that the osteogenic media method with hUCMSCs in
CPCF was promising for bone regeneration, and that hUCMSCs represent a desired
alternative to the gold-standard bone marrow MSCs because the former do not require an
invasive procedure to harvest.150 Next, the following researchers used tricomponent
systems with similar composition, but different fabrication method to ours: Lian et al.
reinforced self-hardened calcium phosphate cement, CPC with collagen-coated chitosan
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fibres to reach a fiber volume content of 5%.151 They achieved compressive strength of
the CPC-fibre implant fourfold higher than that of the CPC control (33 MPa when the
strain was 2.4 per cent ).151 This value is about 6 x less than that for human bone.152 Nine
cylindrical implants including six CPC-fiber implants were implanted into bone defects
of nine dogs and were then post-operatively observed.151 After 20 weeks in vivo, new
callus from the healthy tissue of the defect entirely integrated with the CPC-fiber implant
and new bone was formed as the implant degraded, thus facilitating bone process repair
in vivo.151 Further, Li et al. created a novel salmon calcitonin-loaded bioactive injectable
calcium phosphate cement for treating an osteoporosis-induced bone defect.153 The
injectable time for the cement is 12 minutes, the compressive strength is low for a loadbearing application (12 MPa), the final setting time is 40 minutes and the release of the
containing salmon calcitonin was controlled easily through adjusting the ratio of chitosan
oligosaccharide and collagen polypeptide.153
Although chitosan and collagen were used in scaffolds with or without growth
factor delivery, no mechanical testing was performed. For example, chitosan/collagen
scaffolds were fabricated by a freeze-drying method and were loaded with VEGF
protein and adenovirus expressing BMP-2.146 The in vitro study revealed a burst and
rapid release of VEGF with a sustained high-level expression of BMP-2, while the in
vivo study showed the scaffolds enhanced bone formation, bone-to-implant contact and
mean peak removal torque when compared to other groups.146
Ravindran et al. developed a novel collagen/chitosan template that is embedded
within the native extracellular matrix, ECM of differentiating human marrow stromal
cells (HMSCs) to facilitate osteoblast differentiation.154 Gene expression analysis
showed that the ECM scaffold supported osteogenic differentiation of undifferentiated
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HMSCs and the nucleation of calcium phosphate polymorphs to form a mineralized
matrix, which is promising for bone tissue engineering.154
Recently, Pallela et al. created a scaffold containing chitosan, hydroxyapatite and
marine sponge collagen using the lyophilization method.155 The interconnected porosity
was 50-170 µm and the human osteosarcoma, MG-63 cell proliferation was higher than
on pure chitosan, which makes these composite scaffolds promising for matrix-based
bone repair and bone augmentation.
Moreover, a new delivery system for multiple bioactive factors and an inductive
implant scaffold for bone regeneration was invented by Niu et al.156 Compared with the
rapid release from chitosan microspheres (CMs), the bone morphogenetic protein-2derived synthetic peptide was delivered from CMs incorporated into
nanohydroxyapatite/collagen (nHAC), and poly(L-lactide), CMs/nHAC/PLLA
microsphere-scaffold composite in a temporally controlled manner, depending on the
degradation of both incorporated CMs and PLLA matrix.156 The results indicated that,
with the appearance of CMs in microsphere-scaffold composite, the MC3T3-E1
osteoblasts exhibit better morphology and proliferation ability. Moreover, it was
demonstrated that the CMs/nHAC/PLLA scaffolds possess better biocompatibility in a 6
mm rabbit femoral condyle defect, which should be attributed to both the incorporated
chitosan component and the encapsulated bioactive synthetic peptide. 156
Zhang, Wang and coworkers used chitosan (CS) as a dispersant in a bone matrix
constructed with collagen (Col) and hydroxyapatite (HA).157,158 Solid-liquid phase
separation was used to shape a three-dimensional porous structure to support cell
growth.157,158 Mesenchymal stem cells proliferated more with spreading and ECM
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secretion along collagen fibers and the scaffolds repaired a 1.0x.6 cm2 bone defect in the
mandibles of rabbits in 3 months.157,158
All in all, none of the above scaffolds possess load bearing abilities and most of
them don’t present the degradation needed to see if the scaffolds are suitable for bone
regeneration.
2.8 Conclusions
The above articles summarize the benefits of using chitosan and collagen or
chitosan, collagen and a crystalline form of calcium phosphate for bone tissue repair:
osteogenic differentiation of undifferentiated human mesenchymal stem cells, the
nucleation of calcium phosphate polymorphs to form a mineralized matrix, induction of
biomimetic deposition of calcium phosphate, better morphology and proliferation ability
of osteoblasts, enhanced bone formation, bone-to-implant contact and mean peak
removal torque, higher expression of osterix and bone sialoprotein genes in medium with
and without osteogenic supplements, higher phosphatase activity and calcium deposition
in osteogenic medium and finally, healing a bone defect completely. We hope to adopt a
similar strategy by preparing composite chitosan-collagen-calcium phosphate
microspheres using a unique method of incorporating collagen within chitosan
microspheres via a precipitation method. The addition of collagen to chitosan and
calcium phosphate will help increase the degradation rate of chitosan scaffolds without
compromising the overall mechanical strength. Although chitosan and the denatured
form of collagen, gelatin, have been used for cartilage tissue engineering, the addition of
calcium phosphate can improve the mechanical strength and make the present
tricomponent scaffolds suitable for bone tissue engineering. Thus, this study would
provide data on the potential of using a composite chitosan-collagen-calcium phosphate

38

system as a bone graft substitute for bone tissue plerosis for the treatment of non-unions
and bone defects.
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CHAPTER 3: MATERIALS AND METHODS

Part 1. Microspheres’ Fabrication, Characterization, Degradation and Cell
Culture.
Preparation of Composite Chitosan-Collagen-Calcium Phosphate Microspheres
Chitosan-calcium phosphate and chitosan-collagen-calcium phosphate
composite microspheres were made based on the co-precipitation technique, as
previously described.33 To make chitosan-calcium phosphate microspheres, a 2.67 %
solution of chitosan powder (61% DDA, MW=220 kDa, Primex, Siglufjordur, Iceland)
was prepared in 2 v/v% acetic acid solution and allowed to dissolve for 24 h. CaCl2 and
NaH2PO4 were added to achieve a 0.06 M Ca2+ and 0.03 M PO43- with a Ca:P=2. The
solution was filtered through a nylon mesh with a pore diameter of 180 µm (Gilson
Company, Inc., Ohio, USA). For the chitosan-collagen-calcium phosphate composites,
an appropriate volume of 0.03% collagen in 2% CH3COOH was mixed manually with
the filtered chitosan solution to achieve 10 or 25 wt% collagen. Note: a 3.16 wt%
chitosan solution was used for making microspheres with 25 wt% collagen.
Using a KDS 200 two-syringe infusion pump (KD Scientific, Holliston, MA),
the chitosan solutions were dripped at 4°C through a 21G needle (BD Medical, Franklin
Lakes, NJ) into a base solution of 20 mass% NaOH, 30% CH3OH and 50% H2O at
flow rates between 0.15-0.29 mL/min to precipitate the chitosan-based composites into
beads with a spherical shape. The microspheres were stirred in the base solution for 1020 min. before being washed with copious volumes of distilled water, dH2O, until a
pH=7.4-7.8 was obtained. The last wash was in deionized water, DI H2O. The chitosancomposite microspheres were air dried in a fume hood overnight.
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Ash Content for the Determination of Calcium Phosphate in Microspheres
The amount of calcium phosphate salts/mineral present in the microspheres was
determined using a combustion method.159 Approximately 0.5 g beads were weighed and
heated for about 2 h at 60⁰C under vacuum until the mass change was less than 0.1% to
remove excess moisture. Clean ceramic crucibles were weighed and placed into a high
temperature oven at 550±20⁰C for 30 min. The crucibles were allowed to cool in a
desiccator for 30 min. The crucibles were re-weighed and the heating process was
repeated until a constant mass for the crucible was reached (<0.1% mass change). The
microspheres were transferred to a crucible and combusted by placing the crucible over a
Bunsen burner. The crucibles were then transferred to a high temperature oven at
550±20⁰C for 3 hours (h). The crucibles were cooled down in a desiccator and the heating
process was repeated until constant mass was reached (<0.1% mass change). The
percentage of ash was calculated using the formula:
Ash content (%) =

m 2  m0
 100
m1

Where m0 is the constant mass of the crucible (g), m1 is the mass of the sample (g)
and m2 is the constant mass of the ash and crucible (g). Three samples were used to
determine the ash content of each of the three chitosan composite groups plus a control,
which consisted of chitosan beads with no calcium phosphate to account for salts or other
impurities in the initial chitosan powder.
Hydroxyproline Assay for the Determination of the Amount of Collagen Incorporated
The hydroxyproline assay160 was used to estimate the amount of collagen
incorporated into the microspheres due to the high levels of the amino acid found in the
collagen polymer. Approximately 0.1 g of each type of composite beads were weighed
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and heated for about 2 h at 60⁰C under vacuum until the mass change was less than 0.1%.
This was done to remove excess moisture in the beads. Teflon tape was applied to the
threads of 2-mL screw cap microcentrifuge tubes (PCR-PT from SARSTEDT, Germany)
which contained O-rings inside the caps to withstand positive pressure. The beads were
transferred to the microcentrifuge tubes and approximately 1.9 mL of 6M HCl was added
to each tube. The tubes were placed in a high heat resistant glass bottle to equalize
pressure during incubation at 110⁰C for at least 16 h. This was done to hydrolyze the
proteins into amino acids. After cooling to room temperature, the samples were
centrifuged for 10 min. at 14,000 RPM to separate particulates from the aqueous solution
containing hydrolyzed amino acids. 1 mL of the aqueous solution was transferred to a 15
mL centrifuge tube and 4 mL DI H2O was added. The solution was placed in a -80⁰C
freezer for at least 1h and lyophilized in a 2.5 L Labconco freeze dryer. The lyophylization
procedure was repeated in order to remove the residual acid. The resulting hydrolyzed
amino acid powder was solubilized in 1 mL of DI H2O, vortexed and then a 25 µL aliquot
was added to a well of a 96-well plate. A 112.5µl volume of chloramine-T reagent was
added to each test sample and incubated from 20 min at room temperature to oxidize the
hyroxyproline to a pyrrole derivative. Then 125 µL of Ehrlich’s reagent was added to each
sample, heated in an oven at 65⁰C for 20 min. to generate a colored chromagen product.
The absorbance was read at 550 nm. Absorbance was converted to µg/mL hydroxyproline
using hydroxyproline (Sigma-Aldrich) standards. The collagen concentration was
calculated taking into account that the measured hydroxyproline is 10.8% in collagen.161
The concentration of collagen in the microspheres was determined based on the mass of
collagen from the assay and the initial mass of microspheres without calcium phosphate
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given by the ash content assay. Triplicate samples were measured for each composite
group.
Shape Characterization
Images of the microspheres were obtained with a KEYENCE VHX 1000 digital
microscope. 40 samples from each group were placed on a weigh boat and viewed with
a 100x objective eyepiece (200x objective for close-up). Since the microspheres
exhibited elliptical shapes, the length of the major and minor axis of the microparticles
were measured and used to calculate a sphericity index based on the following equation:
Sphericity index=

major axis
.
minor axis

X-ray Diffraction Analysis
To check for the presence of chitosan and calcium phosphate crystalline
structures composite microspheres were examined by x-ray diffraction using a Bruker
D8 Advance Diffractometer (Bruker AXS Inc., Madison, WI) using Cu-Kα radiation at
40 kV and 40 mA. Prior to XRD analysis, approximately 5 mg of each type of
microsphere (n=2) were placed in a micro centrifuge tube and then immersed for 5 min.
in liquid N2. The frozen microspheres were then ground into fine powder using a pestle
and mortar. The diffraction patterns of the powders were obtained in the scan range
2θ=5-40⁰ with a step size of 0.04⁰ and a time/step of 0.302 s.
In Vitro Degradation of Composite Chitosan-Collagen-Calcium Phosphate
Microspheres
The in vitro degradation of composite chitosan-collagen-calcium phosphate
microspheres was based on change in mass over a 6-week period. All the samples were
gamma sterilized prior to starting the study by irradiating at 32 kGy for 2h. The
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degradation solution used consisted of 50 µg/mL collagenase type IA (Clostridium
hystoliticum, Sigma Aldrich) and 100 µg/mL lysozyme in 1x PBS supplemented with
Penicillin-10,000 IU/mL, Streptomycin-10 mg/mL, Amphotericin B-25 µg/mL. As
control, microspheres of each type were also incubated in PBS with
antibiotics/antimycotic (AB/AM) but without enzymes.
Approximately 30 mg samples (n=4) for each of the composite chitosan-collagencalcium phosphate treatment group were weighed and exact mass recorded, and then
placed in 1.5 mL microcentrifuges. To each sample of microspheres, 1.5 mL of
degradation solution were added and the samples were placed in an incubator at 37⁰C
with constant shaking using a plate rocker. The degradation solution was changed every
2-3 days in order to avoid the complete loss of enzymes’ activity. At 1, 3, 5, 7, 14, 21, 28
and 42 days, the samples were washed with DI H2O five times to remove any precipitated
salts and proteins before drying in an oven at 40⁰C for at least 24 h. The samples were
then weighed and the percent change in mass was calculated from the initial mass. The
data was reported as percent mass loss ± standard deviation.
In Vitro Cytocompatibility of Composite Chitosan-Collagen-Calcium Phosphate
Microparticles and Scaffolds
The cytocompatibility of the gamma-sterilized composite chitosan-collagencalcium phosphate microspheres was evaluated using a murine fibroblast cell line
(NIH/3T3, ATCC® Number: CRL-1568™) and a human osteosarcoma cell line (Saos-2,
ATCC® Number: HTB-85™). The cell attachment and growth study was conducted in
complete growth medium composed of Dulbecco’s Modified Eagle’s Medium with 10%
FBS and 1x antibiotic/antimycotic for NIH/3T3, and McCoy’s 5A Medium with 15%
FBS and 1x antibiotic/antimycotic for Saos-2.
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Briefly, 60 microspheres of each sample group were placed in glass culture tubes,
13 x 100mm with screw cap (PYREX® Laboratory Glassware, CORNING, MA USA).
The microspheres were soaked in 200 µL complete growth medium for 3-4 h. Then, the
medium was removed and 2 mL of medium with cells (3.9 x 105 NIH/3T3 cells/mL or
1.5 x 105 Saos-2 cells/mL) were added. The tubes were placed in an incubator (Model
3158, Forma Scientific, Marietta OH) at 37°C and 5%CO2. After 4 h incubation, cell
attachment to microspheres was measured using the CellTiter-Glo® Luminescent Cell
Viability Assay (Promega, WI, USA). The assay estimates number of cells based on the
presence of ATP via the luciferase-luciferin reaction. The growth medium was replaced
every 2 days for NIH/3T3 and every 3 days for Saos-2. After 1, 3 or 7 days cell
proliferation was measured using the CellTiter-Glo® Luminescent Cell Viability Assay.
The seeding concentration for proliferation for fibroblasts was 1.8 x 105 cells/mL and for
osteoblasts, 1.2 x 105 cells/mL. The data for attachment was reported as % cell attached
± standard deviation, while for proliferation the data was reported as # cells
/microparticle ± standard deviation.
In addition, at each time point, samples of each chitosan composite
microsphere were evaluated using a LIVE/DEAD® Viability/Cytotoxicity Kit for
mammalian cells (Invitrogen Corporation, CA, USA) to determine the viability of
cells based on plasma membrane integrity and esterase activity of the cells.
Statistical Analysis
Regression analysis was used for the degradation of microparticles, one-way
ANOVA & post-hoc tests were used in SigmaStat 3.5 to evaluate the % cell attachment
on beads for both cell types. For cell proliferation studies on microparticles a two-way
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ANOVA with Tukey’s post-hoc test was used. A p value < 0.05 was considered
significant.

Part 2. Scaffolds’ Fabrication, Characterization, Physical and Mechanical
Properties, Degradation and Cell Culture.
Scaffold Fabrication
Microspheres for each type of composite were made as described in the section
“Preparation of Composite Chitosan-Collagen-Calcium Phosphate Microspheres“. To
make scaffolds, 40 mg beads were fused with 1 drop of either 1 v/v% acetic acid,
CH3COOH or 2 v/v% glycolic acid, HOCH2CO2H and packed into a cylindrical mold with
an inner diameter of 6 mm and height of about 15 mm. Scaffolds were gamma-sterilized at
32 kGy for 2h and kept sealed at room temperature for one week before degradation. The
scaffolds for cell attachment and proliferation were kept at room temperature for one
month before the experiments and the scaffolds for mechanical testing were kept at room
temperature for six weeks before mechanical testing. The scaffolds had a height twice the
diameter (approximately 14 mm tall by 6 mm diameter) to follow ASTM D695 - 10
Standard Test Method for Compressive Properties of Rigid Plastics.
Morphological Characterization
Images of the scaffolds were obtained with a KEYENCE VHX 1000 digital
microscope. The samples (n=5) were placed on a weigh boat and viewed with a 100x
objective eyepiece (200x objective for close-up). A rough estimate of the size of the pores
was obtained from the small sequence of images taken (n=5). The longest distance in the
pore was measured.
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Porosity Determination
The porosity was determined by liquid volume displacement method using a
density determination kit (Mettler Toledo, Switzerland), with a Mettler Toledo balance.
The diameter and height of the cylindrical scaffolds were recorded and methanol was
poured in the beaker where the gem holder was immersed, to cover the wire basket of the
gem holder by at least 1 cm. The temperature of the room was recorded in order to have
the correct value for the density of methanol. The gem holder was attached and the
balance was tared to read 0. The dry scaffold was placed in the upper cup of the gem
holder and the mass recorded as mass A in mg. The balance was tared again, the scaffold
was placed in the beaker and the beaker with methanol and a scaffold were placed under
vacuum and kept for 4 min. to remove bubbles entrapped in the porous scaffold. The
scaffold was placed in the wire basket in methanol and the mass, P or buoyancy was
recorded. The density was calculated by the formula:



A   CH3OH
P

,

Where A and P are the masses recorded as indicated above, ρCH3OH is the density of
methanol, which at 21⁰C is 0.7918 g/cm3. The total volume of the cylindrical scaffold was
calculated using the following equation:

Vtot 

  D2  H
4

,

Where D=diameter of the scaffold and H=height of the scaffold.
The volume without pores was calculated using the formula:
Vwithout pores=

A



,

Where the mass A and the density ρ are previously defined.
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The porosity was calculated using the formula:
Porosity=

Vtot Vwithoutpores
Vtot

 100

This measurement was done for n=10 scaffolds from each group.
Mechanical Testing
The compressive modulus of scaffolds was determined using an Instron load frame
(Model #33R 4465). The scaffolds had a height twice the diameter (approximately 14 mm
tall by 6 mm diameter) to follow ASTM D695 - 10 Standard Test Method for Compressive
Properties of Rigid Plastics. A 500 N load cell of the Instron was operated at a rate of 1
mm/min. The scaffolds were hydrated for 25 h in dH2O prior to testing. The scaffolds were
conditioned by first compressing samples by 5% of the height, and then unloaded. Test
specimens were then compressed up to 50% of the height with Teflon tape above and
below the scaffold to allow for equal load distribution. The compressive stress and strain
were recorded and Young’s modulus was calculated for n=10 replicates for each type of
scaffold.
In Vitro Degradation of Composite Chitosan-Collagen-Calcium Phosphate scaffolds
The degradation of the scaffolds was evaluated over a 4 week-period by
measuring the change in mass at 1 week-intervals. All the samples were gamma
sterilized at 32 kGy for 2h prior to starting the study. The degradation solution used
consisted of 50 µg/mL collagenase type IA (Clostridium hystoliticum, Sigma Aldrich)
and 100 µg/mL lysozyme in 1x PBS supplemented with Penicillin-10,000 IU/mL,
Streptomycin-10 mg/mL, Amphotericin B-25 µg/mL. As control, scaffolds of each
type were also incubated in PBS with antibiotics-antimycotic, but without enzymes.
Samples (n=4) for each of the composite chitosan-collagen-calcium phosphate
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treatment group were weighed (~ 40 mg) and placed in glass scintillation vials. To each
scaffold, 3 mL of degradation solution were added and the samples were placed in an
incubator at 37⁰C with constant shaking using a plate rocker. The degradation solution
was changed every 2-3 days in order to avoid the complete loss of enzymes’ activity. At
each time point, the samples were washed with 15 mL DI H2O before drying in an oven at
40⁰C for at least 24 h, weighed and the percent change in mass was calculated. The data
was reported as percent mass loss ± standard deviation.
In Vitro Cytocompatibility of Composite Chitosan-Collagen-Calcium Phosphate
Scaffolds
The cytocompatibility of the gamma-sterilized composite chitosan-collagencalcium phosphate scaffolds was evaluated using a human osteosarcoma cell line (Saos2, ATCC® Number: HTB-85™). The cell attachment and growth study was conducted
in McCoy’s 5A Medium with 15% FBS and 1x antibiotic/antimycotic.
Each scaffold (~40 mg) was soaked for 17 h in 2 mL medium in a well of a 24
well plate so that proteins would attach to scaffolds and the cells wouldn’t fall off during
the swelling of the scaffolds. The medium was removed, 1.5 mL sterile PBS was added
so that residual acetic or glycolic acid in the scaffolds will diffuse into the PBS. The
scaffolds were left in the incubator at 37°C and 5% CO2 for 1 h. They were shaken by
hand for a few seconds and the PBS was removed and the scaffolds were seeded with
100 µL with 105 osteoblasts/mL. After 1.5 h, 1 mL medium was added to cover the
samples in the wells. The medium was replaced every 3 days. Samples were evaluated at
4 h for cell attachment and at days 1, 3 and 7 for cell proliferation using the CellTiterGlo® Luminescent Cell Viability Assay (Promega, WI, USA). For cell attachment, the
data was reported as mean % cell attachment ± standard deviation, while for cell
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proliferation, the data was reported as mean # cells/scaffold ± standard deviation. At
each time point, the samples were examined for viability using a LIVE/DEAD®
Viability/Cytotoxicity Kit for mammalian cells (Invitrogen Corporation, CA, USA).
Statistical Analysis
A one-way ANOVA & Tukey’s post-hoc tests were used in SigmaStat 3.5 to
evaluate the porosity, Young’s modulus and cell attachment. Regression analysis was
used for the degradation of scaffolds. For Saos-2 proliferation on scaffolds, a two-way
ANOVA with Tukey’s post-hoc tests were used. A p value < 0.05 was considered
significant.
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CHAPTER 4: RESULTS

Part 1. Microspheres’ Characterization, Degradation and Cell Culture.
Representative digital images of the three types of microparticles are shown (Figure 1).
All microparticles present surface texture.

Composition

100x magnification

200x magnification

χtosan-CaP

10Coll-χtosan-CaP

25Coll-χtosan-CaP

Figure 1. Digital images of composite chitosan-collagen-calcium phosphate
microparticles. χtosan-CaP: chitosan-calcium phosphate; 10Coll-χtosan-CaP: 10%
collagen-chitosan-calcium phosphate; 25Coll-χtosan-CaP: 25% collagen-chitosancalcium phosphate. Scale shown: 500 µm.
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Physicochemical characterization
The results of the determination of the shape, collagen content and ash content of
the microparticles are summarized in Table 2. The diameters of the microparticles were
determined with KEYENCE VHX-1000 digital microscope. Because the particles
exhibited ellipsoidal shapes, both the major and minor axes were measured. The ratio of the
major axis to minor axis was used to calculate a sphericity index. The closer the index
value is to 1, the more spherical the particles tend to be. The sphericity index, close to 1.3
for all groups, indicates that the microparticles are ellipsoidal and one-way ANOVA
indicated there was no statistically significant difference in sphericity index between the
three groups.
The ash content of the composite microspheres was determined via combustion
and was used as an estimate of the amount of calcium-phosphate mineral/salt in the
particles. The ash content of plain chitosan beads without calcium phosphate was
subtracted from the three experimental composites to account for any residual
minerals/salts in the starting chitosan material.
The actual amount of collagen incorporated into the composite microparticles was
determined based on the hydroxyproline assay. It was found that the microspheres with
the target 10.0% and 25.0% collagen actually had approximately 2.6% collagen and 7.6%
collagen, respectively. The hydroxyproline assay for the negative control, chitosancalcium phosphate composite beads without collagen, indicated a very low protein
content, 0.024±0.004%, while the positive control, the collagen stock solution, had
89.4±4.7% collagen.
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Table 2. Physical and compositional properties of the chitosan-collagen-calcium
phosphate composite microparticles
χtosan-CaP

10Coll-χtosan-CaP

25Coll-χtosan-CaP

Sphericity Index

1.35±0.21

1.35±0.21

1.31±0.19

Major axis (µm)

986±118

998±92

937±95

Minor axis (µm)

736±75

751±103

726±85

Ash (%)

8.94±0.50

6.77±0.82

9.13±1.16

theoretical

0

10.0

25.0

empirical

0.024±0.004

2.6±0.2

7.6±0.8

Coll
(%)

X-ray diffraction (XRD) analysis was used to identify crystalline phases present in
the different microparticle composite formulations. Representative XRD spectra of the
different composite materials are shown in Figure 2. The peaks at 2θ~11° and 2θ~20° are
indicative of the hydrous and anhydrous peaks of chitosan respectively.40 In the spectra for
the chitosan-calcium phosphate composite microparticles, two additional peaks at 2θ~32°
and at 2θ=34.4° were observed. The peak at 2θ~32° corresponds to the (211) plane of
hydroxyapatite (HA) and the peak at 2θ=34.4° corresponds to the (220) plane of
tricalcium phosphate (TCP).162 The presence of these peaks indicates that calcium
phosphate is present partly in crystalline form. With the addition of increasing amounts of
collagen, both the chitosan and the HA peak at 2θ~32° and TCP peak at 2θ=34.4° reduced
in intensity until they disappeared for 25% collagen.
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Figure 2. Representative XRD spectra of composite chitosan-collagen-calcium phosphate
microparticles compared with chitosan. A shift in the hydrous peak of chitosan from
2θ=10⁰ to 2θ=11⁰ is observed, while the anhydrous peak is noticed at 2θ=20⁰. The peak
at 2θ=32° corresponds to the (211) plane of hydroxyapatite (HA, in green) and the
peak at 2θ=34.4° corresponds to the (220) plane of tricalcium phosphate 162 (TCP,
in dark blue).

Degradation study
The total mass loss seen after 6 weeks in both degradation solutions is
summarized in Table 2. ANOVA analysis indicated that all groups lost significantly
more mass in the solution with enzymes than in the plain PBS solution. For the
microparticles in PBS with enzymes (Figure 3) and in the control solution (Figure 4),
regression analysis showed a significant loss in mass overtime for all composite groups
(p<0.05), but there were no statistically significant differences in degradation between
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groups (p>0.05). A two-way ANOVA with post hoc test showed there is a statistically
significant increase in degradation in PBS + enzymes versus the control solution
(p≤0.001, Table 3).

Table 3. The change in mass of beads in PBS only vs. degradation solution
respectively, after six weeks.
Δmassmicroparticles (%)
solution

χtosan-CaP
a

Control (PBS)

10.0±6.8

enzymes

20.5±4.1b

10Coll-χtosan-CaP
13.2±2.2

a

18.5±3.2b

25Coll-χtosan-CaP
8.3±3.7a
20.0±4.3b

a and b superscript letters indicate statistical differences between degradation solution
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Figure 3. Degradation of microparticles in PBS + enzymes. Tukey’s test and one-way
ANOVA showed that all initial masses are statistically different (p<0.05). Regression
analysis showed that the degradation rates are similar (α=0.05). n=4

55

20

χtosan-CaP
10Coll-χtosan-CaP
25Coll-χtosan-CaP

15

%Δmassmicroparticles

10

5

0
1

3

5

7

14

21

28

42

-5

time (days)
-10

Figure 4. Degradation of microparticles in PBS. One-way ANOVA and Tukey’s test
showed that all initial masses are statistically different (p<0.05). The beads showed a
loss of mass over time. Regression analysis163 showed there were no differences in the
degradation rate (p<0.05). n=4
Osteoblast and fibroblast attachment and proliferation on microparticles
Cellular attachment and proliferation studies on microparticles were performed with two
cell lines: NIH/3T3 murine fibroblasts and Saos-2 human sarcoma osteoblasts.
For the attachment of both fibroblasts and osteoblasts on microparticles, one-way ANOVA
analysis, followed by Tukey’s multiple comparison test showed there is no difference in
percentages of cells attached on the 3 groups of microparticles (Figure 5, 6). More
fibroblasts than osteoblasts seem to have attached to the microparticles (one-way ANOVA,
p<0.05), without taking into account initial cell seeding concentration.
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Figure 5. Fibroblasts’ attachment (%) on beads. One-way ANOVA analysis,
followed by Tukey’s and then Bonferroni’s t-tests showed there is no difference
between groups for α=0.05 (n=5).
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Figure 6. Osteoblasts’ attachment (%) on beads. One-way ANOVA analysis,
followed by Tukey’s multiple comparison test showed there is no difference
between groups for α=0.05 (n=4).

Overall, cells proliferated on all treatment groups of microparticles over the 7 day-cell
culture period, but there was no statistically significant difference between groups for
fibroblasts (Figure 7) or osteoblasts (Figure 8). At the end of a week, fibroblasts increased
5x in number and osteoblasts multiplied 3-4x on microparticles.
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Figure 7. Fibroblasts’ proliferation on beads. Regression analysis showed no
significant difference between groups for NIH/3T3 cells (p<0.05), while one-way
ANOVA showed an increase with time: †=difference between all previous time
points (p<0.0005), n=4 (except day 1, where n=3 and 10% collagen microparticles
on day 7, where n=2).
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Figure 8. Osteoblasts’ proliferation on beads. Two-way ANOVA showed that
there is a statistically significant increase in osteoblast numbers per day (p<0.001),
which means that cells proliferate, but there is no difference between the different
bead types. †=difference between all previous time points (p<0.001), n=4.

58

A representative LIVE/DEAD image of cell viability on constructs, taken using a
Nikon ECLIPSE TE300 microscope with BIOQUANT OSTEO II software, is shown in
Figure 9.

bead

Figure 9. Fibroblasts’ viability on 25% collagen-chitosan-calcium phosphate
microparticles after one week. Light green dots represent fibroblasts.

Part 2. Scaffolds’ Characterization, Physical and Mechanical
Properties, Degradation and Cell Culture.
Representative digital images of scaffolds made of the three different bead types
fused with either acetic acid or glycolic acid are shown (Figure 10). From the small
sequence of images taken (n=5/scaffold type), the pore size in the gamma-sterilized
scaffolds is estimated to be between 100-400 µm. Scaffolds fused with acetic acid
appeared darker brown as compared to the scaffolds fused with glycolic acid, which had a
lighter brown/yellow appearance. Some of the scaffolds are covered in a sheet of melted
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chitosan right next to where the walls of the mold that held the scaffold were. The sheet
may result from addition of more acid solution than needed in fusion.

χtosan-CaP

10Coll-χtosan-CaP

25Coll-χtosan-CaP

Type of acid

Acetic

Acetic,
close up

Glycolic

Glycolic,
close up

Figure 10. Digital images of composite chitosan-collagen-calcium phosphate scaffolds:
100x magnification and close up (200x magnification) to show pore structure. Scale
shown: 500 µm.

In order to see if the scaffolds may allow cell migration, growth and also allow for
diffusion of nutrients and waste products, the porosity of the scaffolds was measured using
a density determination kit. Two-factor ANOVA using the composition of microparticles
as one factor and the type of acid used for fusing as another factor, indicated that there
were differences in porosity of the scaffolds based on composition (p = 0.03), no
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differences based on type of acid used for fusing (p=0.3), and there was a significant
interaction between the composition and type of acid used for fusing (p=0.02). Due to
interaction, separate one-factor ANOVA’s for the type of fusing acid were performed.
One-factor ANOVA of acetic acid-fused scaffolds indicated that there was no significant
difference in the porosity of the scaffolds due to composition (p=0.4). However, one factor
ANOVA analyses of the glycolic acid fused scaffolds indicated that there was a difference
in porosity of the scaffolds (p=0.0002). Tukey’s post-hoc test indicated that 25Collχtosan-CaP, gly_ac had higher porosity than the χtosan-CaP, gly-ac group but no
difference in porosity was observed between the 25Coll-χtosan-CaP and the 10Collχtosan-CaP or between 10Coll-χtosan-CaP and the χtosan-CaP groups (Figure 11).

61

40

*

35
Porosity (%)

30
25
20

15
10
5
0

Figure 11. Porosity of scaffolds made of chitosan, 10% collagen or 25% collagen and
fused with either acetic acid or glycolic acid. Acet_ac: acetic acid; glyc_ac: glycolic
acid. Two-way ANOVA showed that the porosity of scaffolds among the different
levels of composition was different (p=0.032), but that based on fusion was not
statistically significant. The porosity of 25% collagen-chitosan-calcium phosphate
beads fused with glycolic acid (28.4% mean porosity) is higher than that of 25%
collagen beads fused with acetic acid and chitosan beads fused with glycolic acid
(p<0.05). *=difference between groups (p<0.005)

To evaluate the load-bearing capacity of the scaffolds, the mechanical properties were
determined in compression. A representative stress-strain curve for the scaffolds is
presented in Figure 12. Two linear regions were observed in the curves for the
scaffolds.
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Figure 12. Representative stress-strain curve for scaffolds. The two rectangles surround
linear portions of the curve.
The linear region at strain=0.05 was used to calculate the compressive modulus.
The 5% strain, which was contained within the first linear region of the stress-strain curve
of the scaffold, was higher than the maximum strain for the linear region of the stressstrain curve for bone, 0.7%.152 This already shows that the stress-strain curve for the
scaffold is different than that of bone. The second linear region observed in compression
tests at higher strains, was associated with the collapse of the composite structure and not
with the properties of the porous scaffold. Two-factor ANOVA indicated that there were
significant differences in the modulus of the scaffolds based on composition, type of
fusing acid, and that there was a significant interaction between the composition and type
of fusing acid (p≤0.001). Due to interaction, separate one-factor ANOVA’s based on the
type of fusing acid were performed. For scaffolds fused with acetic acid, one-way
ANOVA indicated that there were no statistical differences in modulus of the scaffolds
based on composition (p= 0.7), but that glycolic acid-fused scaffolds had lower modulus
than acetic acid-fused scaffolds (p<0.001). For scaffolds fused with glycolic acid,
ANOVA indicated that there were differences in the modulus of the different scaffolds
based on composition (p=0.001). Tukey’s post hoc test indicated a significantly higher
modulus for 10% collagen scaffolds vs. 25% collagen scaffolds and chitosan scaffolds
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(p<0.001). Consequently, χtosan-CaP, acet_ac, 10Coll-χtosan-CaP, glyc_ac and 25Collχtosan-CaP, acet_ac had the significantly higher E (p<0.05) while there was no difference
in E between 25Coll-χtosan-CaP or the χtosan-CaP composite groups (Figure 13).
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Figure 13. Young’s modulus in compression of composite scaffolds. Acet_ac: acetic
acid; glyc_ac: glycolic acid. Two-way ANOVA showed that Young’s modulus was
higher for all three types of microparticles fused acetic acid than that of microparticles
fused with glycolic acid (n=10). Error bars are standard deviations. *=difference
between groups’ means (p<0.001).
Degradation study
In order to see if fusing the different composite microparticles with acids affects
the degradation rate, scaffolds of the three bead compositions fused with acetic acid versus
glycolic acid were degraded in control solution or in degradation solution for 4 weeks.
The results of the scaffold degradation study after 4 weeks are summarized in
Table 4. Three-way ANOVA followed by post-hoc tests showed there is no statistically
significant difference between scaffolds with 10% collagen and chitosan scaffolds, but the
glycolic acid-fused microparticles degraded significantly more than the acetic acid-fused
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ones (p<0.001). There is a significant increase in the %Δmass in degradation solution
versus the control solution (p<0.001). In the degradation solution there is a significant
group x fusion interaction (p≤0.001) and difference among different groups within acetic
acid: 25Coll-χtosan-CaP, acet_ ac vs. 10Coll-χtosan-CaP, acet_ ac (p<0.001) and vs.
χtosan-CaP, acet_ ac (p=0.002) (Table 4). In degradation solution, based on the type of
acid used for fusion, chitosan and 10% collagen scaffolds fused with glycolic acid
degraded significantly quicker than those fused with acetic acid.

Table 4. The change in mass of scaffolds fused with either acetic or glycolic acid for PBS
+ enzymes and PBS degradation solution only, respectively, after four weeks.
Δmassscaffolds (%)
10Coll25CollχtosanχtosanχtosanCaP, glyc_
CaP, acet_ CaP, acet_
ac
ac
ac

10CollχtosanCaP, glyc_
ac

25CollχtosanCaP,
glyc_ac

solution

χtosanCaP, acet_
ac

control

1.8±0.6

2.4±2.0

1.0±1.1

6.1±5.0

9.4±2.6

2.5±2.8

enzymes

10.7±2.5

11.5±2.0

18.3±1.2

23.0±2.6

25.8±3.4

21.3±2.5

Regression analysis showed significant increase in the degradation profile (p<0.05)
in the enzymes’ solution based on composition: chitosan and 10% collagen fused with
glycolic acid vs. acetic acid (Figure 14). The scaffolds degraded with time. χtosan-CaP,
glyc_ac and 10Coll-χtosan-CaP, glyc_ac exhibited the highest degradation rate:6.5-6.6
%Δm/day.
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Figure 14. Degradation of scaffolds in PBS + enzymes.

Tukey’s multiple comparison test showed that the initial masses are similar (α=0.05).
Regression analysis showed degradation rates are significantly higher for:


Chitosan fused with glycolic acid vs. chitosan fused with acetic acid (p<0.05)



10% collagen fused with glycolic acid vs. chitosan fused with acetic acid
(p<0.05)



Chitosan fused with glycolic acid vs. 10% collagen fused with acetic acid
(p<0.05)



10% collagen fused with glycolic acid vs. 10% collagen fused with acetic acid
(p<0.05)

ANOVA analysis showed significant interaction or difference in the degradation
profile in PBS based on acetic acid (Figure 15). It also showed increased degradation with
time and it distinguished between different degradation groups; χtosan-CaP, acet_ac,
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10Coll-χtosan-CaP, acet_ac and 10Coll-χtosan-CaP, glyc_ac displayed the highest
degradation rate: 2.0-2.4 %Δm/day.
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wk 4
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glyc_ac

-4
-6

10Coll-χtosan-CaP,
glyc_ac

PBS

Figure 15. Degradation of scaffolds in PBS.

Tukey’s multiple comparison test showed that the initial masses of 25% collagen beads
fused with glycolic acid are significantly higher than chitosan beads fused with glycolic
acid (p<0.05).
Regression analysis showed degradation rates are significantly higher for:


Chitosan fused with acetic acid vs. 25% collagen fused with acetic acid
(p<0.05)



10% collagen fused with acetic acid vs. 25% collagen fused with acetic acid
(p<0.05)



10% collagen fused with glycolic acid vs. 25% collagen fused with acetic acid
(p<0.05)
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Osteoblasts’ attachment and proliferation on scaffolds
For osteoblasts attached on scaffolds, the groups were significantly different
(p<0.05, one-way ANOVA) and Tukey’s test showed a higher attachment for acetic acidfusion vs. glycolic acid-fusion of the chitosan microparticles. Post hoc analysis showed
there was attachment was higher for 10% collagen microparticles fused with glycolic acid
than both 10% collagen and 25% collagen microparticles fused with acetic acid, and that
attachment on chitosan microparticles fused with acetic acid was higher than 10%
collagen microparticles fused with glycolic acid (Figure 16). Chitosan microparticles
fused with either acid and 25% collagen-chitosan-calcium phosphate microspheres fused

% osteoblasts attached, scaffolds

with glycolic acid displayed the highest cell attachment: 2.7±1.2%.
4.5
4
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*
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0

Figure 16. Osteoblasts’ attachment on scaffolds (n=4, except chitosan-calcium
phosphate microparticles fused with acetic acid, where n=3). *= difference between
groups (p<0.05)
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Overall, cells proliferated on all treatment groups of scaffolds over the 7 day-cell
culture period (Figure 17). At the end of a week, osteoblasts proliferated 4-7x on scaffolds
(only twice on 10% collagen microparticles fused with glycolic acid). Regression analysis
showed a difference on osteoblasts’ growth based on group for 10% collagen-chitosancalcium phosphate scaffolds. Tukey’s multiple comparison test showed significantly
higher number of osteoblasts/scaffold with time for all scaffolds except for 10% collagen
microparticles fused with glycolic acid (p<0.05). There were no statistical differences
between day 1 and day 3 for all scaffold groups except the above-mentioned 10% collagen
microparticles fused with glycolic acid. Moreover, there was no significant difference
between day 3 and 7 for chitosan microparticles fused with glycolic acid.
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Figure 17. Osteoblasts’ growth on scaffolds. Regression analysis showed the number of
osteoblasts increased with time (p<0.05) and the cell proliferation rate is higher for:
chitosan fused with acetic acid than 10% collagen fused with glycolic acid; 10% collagen
fused with acetic acid than 10% collagen fused with glycolic acid; 25% collagen fused with
acetic acid than 10% collagen fused with glycolic acid. *=difference between groups
(p<0.05), n=4.
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CHAPTER 5: DISCUSSION
A bone graft should possess adequate porosity, degradability, biocompatibility and
initial mechanical strength to provide a framework for cells to attach and proliferate while
maintaining bone volume/shape.76 The predecessors of the present scaffolds showed
promising results. When compared to plain chitosan scaffolds, the predecessor composite
chitosan-hydroxapatite scaffolds exhibited rougher surface and greater surface area for cell
attachment, about 3x higher Young’s modulus and increased pre-osteoblast
proliferation.107 The chitosan-crystalline calcium phosphate scaffolds were tougher and
more flexible than what has been reported for pure calcium phosphate scaffolds.107
Chitosan-hydroxyapatite scaffolds developed by Chesnutt et al.,107 Reves42 and Nguyen164
suffered from low degradation and mechanical strength. The mechanical strength of the
scaffolds was higher than that of hydrated chitosan/collagen hydrogels (18.9 kPa)147 and
that of Infuse® Bone Graft, which is essentially a collagen sponge, with properties up to 1
kPa.165
Additionally, Reves et al. noticed decreased cytocompatibility with the presence of
hydroxyapatite (unpublished results).42 To overcome these limits and improve on the
degradation and cytocompatibility of microsphere-based scaffold design, this research
incorporated collagen, a biodegradable native component of bone that shows excellent
attachment and interaction with cells,146,147,151,153-157,166 into the chitosan-calcium
phosphate microparticles. Further, for increased mechanical strength, we hypothesized that
fusion with glycolic acid would melt chitosan-collagen-calcium phosphate beads more
than acetic acid, providing higher Young’s modulus than acetic acid fusion.
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Part 1. Microparticles
The hydroxproline assay showed that approximately 25.5-30.3% collagen was
incorporated into beads based on initial collagen amount added to composite solution mix.
It has been observed that human bone marrow cells attach to and proliferate better
on rougher hydroxyapatite surfaces as compared smoother surfaces.167 The microparticels
displayed roughness, which may have aided cell attachment. All composite beads
exhibited an ellipsoidal shape with a sphericity index (i.e. major axis: minor axis) of
1.3±0.2. We predicted that the surface tension would gather the chitosan-calcium
phosphate solution drops into spheres. The microparticles looked spherical when hydrated,
but that was not the case in the dry state. Due to the fact that the microparticles were left in
precipitating base solution for a short time to prevent the degradation of collagen, there
was reduced time for induction of chitosan and calcium phosphate crystallinity. The XRD
spectra did reveal decreases in crystallinity for chitosan and CaP in composites, especially
as the amount of collagen increased in the formulation. It may be that the microparticles
flattened out under their own weight during drying.
An aim of this work was to make composite chitosan-CaP materials with either
10% or 25% collagen. Compositional analysis based on the hydroxyproline assay for
collagen and combustion for ash/mineral content indicated that the 10Coll-χtosan-CaP
particles had actual compositions of 2.6±0.2% collagen, 6.8±0.8% CaP and 90.6±0.8%
χtosan and that the 25Coll-χtosan-CaP particles had actual compositions of 7.6±0.8%
collagen, 9.1±1.2% CaP and 83.3±2.0% χtosan.
For both chitosan-collagen composites, 26-30% of the initial collagen was
incorporated into the microparticles. The lower incorporation of collagen in the
microparticles may be due to the following reasons: 1) degradation of collagen in the base
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solution during the 10-20 min. interval the microparticles were in the highly alkaline pH
(~13) and 2) the presence of salts in the lyophilized collagen used to make the beads,
showed by the hydroxyproline assay (10.6%), which was not accounted for when
calculating the mass of lyophilized collagen needed to make 10 or 25% collagen
microparticles.
In determining the mineral content for the composite microparticles due to the
addition of the Ca2+ and PO43- salts, it was noted that the chitosan material itself exhibited
some residual ash content (<0.2%), which was likely due to residual calcium carbonate
from the processing of the materials from original shrimp shells.168 This amount of ash
though was very small (~100x less) relative to the overall ash content measured for
composites made with solutions containing calcium and phosphate salts and was not
considered to add appreciably to the overall mineral component of the composites. All
composite microparticles were loaded with the same amount of salts. The decreased
calcium phosphate of the 10% collagen composites shown by the ash content may really
only be an artifact of the number of washes that were performed to get the pH 7.4-7.8,
which could have washed some of the salt away. Hence, all groups were loaded with a
similar ratio of Ca:P.
The microparticles’ composition does not reflect the relative percentages of
components of native bone, except for collagen. Collagen is 19.8-20.1% of bone47 and
10% of adult bone mass is collagen,169 which explains why we chose 10-25% collagen.
Since the mineral part of bone is underrepresented (6.8-9.1%), an area of improvement is
to use a degradable Mg alloy or porous hydroxyapatite to replace the mineral part of bone
(up to 69%47).
XRD indicated the presence of crystalline chitosan and crystalline forms of CaP
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(e.g. a peak for HA at 2θ=32° with other peaks masked in the background: 2θ=26° and
2θ=40°, and a peak at 2θ=34.4° for TCP). This indicated that even though the beads were
in precipitating solution for a short time, there was some induction of crystalline forms
(the chitosan and HA peaks are similar to those observed by Reves66). The relatively lower
intensity of the CaP crystalline peaks as compared to those seen by Chesnutt40 is reflective
of the lower concentration of crystalline CaP forms which is attributed to the short time in
base solution. The XRD spectra were noisy due to the presence of chitosan. It was
observed that with addition of 10 mass% collagen to the composite, crystalline peaks for
chitosan (2θ=12°, hydrous peak and 2θ=20°, anhydrous peak) and HA/TCP decreased and
disappeared in the 25% collagen composite microparticles. Consequently, the collagencontaining microparticles are more amorphous than chitosan itself, despite chitosan being
a crystalline polymer.170 This suggests that the addition of collagen interfered with or
inhibited the formation of chitosan and CaP crystalline structures. This effect has been
seen by others, e.g. Chen et al.171
In vitro degradation was due to simple hydrolysis and leaching of calcium
phosphate salts/minerals. The degradation was 2.5 times greater in solutions with enzymes
as compared to the control solution without enzymes. This was expected since the
lysozyme and collagenase are the main degradation mechanisms for chitosan and collagen,
respectively. However, it appeared that there was no statistically significant difference in
degradation rates between different microparticles in either the control or the enzyme
degradation solutions. This was contrary to our proposed hypothesis that collagen would
increase degradation. Nevertheless, it was important that the degradation of the
microparticles increased to 20% after 6 weeks. At two weeks, the mass loss of chitosan
beads was 12.5%, 6.25 times higher than that observed by Chesnutt (who saw only 2%
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mass loss over 2 weeks in PBS with 5 times higher lysozyme concentration)107 and Reves,
who did not see mass loss over a month.66 The mass loss of beads at two weeks was
similar (although slightly smaller) to that of chitosan beads without calcium phosphate
prepared by Mecwan (~15%).89 The higher degradation rate may be attributed in part to
the reduced crystallinity of 61% DDA chitosan compared to the 92.3% DDA chitosan
employed by Reves and Chesnutt. The low degree of deacetylation chitosan degrades
faster than high DDA chitosan due to looser chain packing of the polymer, making the
polymer chains more susceptible to enzymatic degradation by lysozyme.66 It is noted that
the chitosan-calcium phosphate microspheres prepared by Chesnutt et al. exhibited a high
chitosan crystallinity index of ~80%.107 The degradation of the composite microspheres in
this study after one month, 15.1±8.5%, was intermediate when compared to those reported
for several types of chitosan/β-TCP/PMMA microspheres prepared via a emulsion method
by Lin L-C et al. which exhibited between 4 and 31% mass loss, with the higher mass loss
associated with lower PMMA.172 However, Lin et al.’s microspheres-cement constructs
exhibited a low porosity and no cytocompatibility is assessed. In another study by Yan et
al., after cross-linking with 0.5% genipin, the degradation degree of 1:1 collagen:chitosan
scaffolds was below 1% in 100 µg/mL collagenase after 12 h,173 which would project to
complete degradation in two months. However, the concentration of the collagenase
solution was twice than that used in the present study and no lysozyme was used. The
limitation of their study was the storage modulus of the collagen-chitosan scaffolds, which
is almost 24000x lower than that of bone, 11 GPa.174
In vitro cell viability studies on composite microparticles were conducted to
observe cytocompatibility. In this study, fibroblast attachment to the microparticles
averaging 40.6±8.0% was similar to 42.21±9.15% HEPM cell attachment to Reves’
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microsphere-based scaffolds66, but was lower than the 60% attachment observed by
Chesnutt,107 which is considered good cell attachment. The osteoblast attachment to the
microparticles, 25.8±8.3% was lower than the fibroblast and HEPM cell attachment. There
was no difference in the attachment or growth of fibroblasts and osteoblasts between the
different composite microparticles. This was contrary to the proposed hypothesis that the
addition of collagen would improve both cell attachment and growth. It is noted that
attachment and proliferation of fibroblasts was greater than that of osteoblasts, but this is
likely due to the difference in initial cell seeding densities, since fibroblasts were seeded at
a higher concentration than osteoblasts. LIVE/DEAD assay confirmed the presence of
cells, although it wasn’t able to show proliferation for all groups. All cells proliferated in
time based on the CellTiter-Glo® Luminescent Cell Viability Assay. The highest cell
increase after a week was seen in fibroblasts on beads, followed by osteoblasts on beads.
The fibroblast proliferation from day 1 to day 7 was 6 fold and the osteoblast proliferation
was ~4 fold, compared to 1.6, 1.5 and 1.9 fold proliferation for MC3T3-E1 on chitosan,
collagen/chitosan, TGF-β1-loaded collagen/chitosan microgranules, respectively.175 The
one-week cell proliferation in this study is higher than the two-week proliferation of
MG63 osteoblast-like cells cultured on collagen–nanohydroxyapatite beads: 1.33x.97 The
fibroblasts and osteoblasts showed adequate proliferation when compared to other cells on
substrates with maximum two out of three components of the present microparticles.97,175
We can conclude that the composite microparticles show improved cytocompatibility.

Part 2. Scaffolds
To make 3D scaffolds, microparticles were fused together by adding dilute acetic
or glycolic acid to make the outer surfaces sticky, and then the microparticles were loosely
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packed together and allowed to dry. The porosity and pore sizes of the scaffolds were
determined based on the Archimedes’ principle and by analyzing images of scaffolds,
respectively. The porosity of the scaffolds was found to range from 19.4±2.6 to 23.4±6.3%
and there were no differences based on either the composition of the particles or the type
of fusing acid used. This porosity is lower than that reported for other microparticle-based
scaffolds: 33.7±5.2–35.8±2.1%.40,42 The lower porosity is largely attributed to the
ellipsoidal shape the microparticles. It has been suggested that a minimum of 30%
porosity is needed to provide sufficient space for bone/tissue ingrowth.80 Improvement in
the shape and/or fusing of the particles will be needed to achieve this minimum porosity
threshold.
Nevertheless, pore sizes for all scaffolds were found to range from 100-400 µm
which are similar to pore sizes reported for other microparticle-based scaffolds (100-800
µm in diameter66,107) and above the minimum 50 µm size reported as needed for
osteogenesis.66 Thus, while the porosity of the scaffolds should be increased, the overall
pore size is adequate for bone tissue engineering applications.
With regard to color hue perception, the darkening of the scaffolds may be an
effect of γ-sterilization.
Ideally, bone scaffolds should be able to bear compressive loads and have enough
porosity to allow bone ingrowth and still provide mechanical stability. High levels of
porosity cannot be reached without compromising mechanical stability of the chitosan
scaffolds. It was suggested that the porosity of bone scaffolds be at least 30%.80 Knowing
that cancellous bone consists of 30% bone and 70% void volume, the scaffolds should
have about 30% porosity to allow for native bone ingrowth, while the scaffolds degrade in
time.176 If needed, the porosity can be increased by making the microparticles spherical.
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Spherical beads can be obtained by lowering the dripping rate on the syringe pumps or by
reducing the volume of acid added to fuse the beads. Less acid for fusion would result in
less bead fusion and larger pores. The porosity of the collagen-chitosan-calcium phosphate
scaffolds was not affected by the acids used to fuse the beads in this study and was slightly
lower than that of chitosan/PLAGA sintered microsphere scaffolds (~35%)177 and lower
than that of other rapid prototyped, lyophilized or other porous formed chitosan-based
scaffolds.90,92,95,96,155 Higher porosity facilitates bone ingrowth better, but that comes with
a cost: decreased stiffness.
Young’s modulus was computed from the lower linear region of the stress-strain
curve because that pertains to the compression of the scaffold with pores (a bone graft
structure that will be seen by bone in vivo). The two values for strain were chosen to be
below the yield strain for bone.152 Even though bone is linearly elastic up to strain of 0.7%
and yields plastically at strains of about 3%,152 the strain values were chosen to be ε=5%
and 10% because they fall in the first linear region of the stress-strain curve for the
scaffolds. Only Young’s modulus at 5% strain is presented. Glycolic acid-fused scaffolds
exhibited lower Young’s modulus except for 10% collagen. The packing of the
microparticles is one of the factors influencing stiffness. Glycolic acid, which is stronger
than acetic acid and whose concentration was twice that of acetic acid in this study, may
have dissolved chitosan and collagen too much, resulting in a weaker structure. The values
of Young’s modulus of the present scaffolds are about 10 times lower than the inferior
limit of the range of compressive elastic modulus reported for cancellous bone: 10-2000
MPa.43 This implies that these scaffolds will need further improvement to be load-bearing.
Even though the moduli of the scaffolds from this study are 9 times lower than those
obtained by Chesnutt et al.,40 9.29±0.8 MPa for rehydrated chitosan-calcium phosphate
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scaffolds, the 20x greater degradation rate of the present scaffolds compensates for the
lower Young’s modulus. In addition, after a month, new bone should infiltrate the scaffold
and start taking a part of the load that was originally only on the scaffold.55,57 Young’s
modulus, E, of the present scaffolds is lower than some bone regeneration biomaterials
containing CaP, PLAGA or PCL29,32,90,121,172 and higher than that of hydrated
chitosan/collagen hydrogels (18.9 kPa)147 (Table 5). Some of the Young’s modulus values
will be over-estimated in case of the dry samples (non-physiologically relevant).

Table 5. Young’s modulus of various bone scaffolds.
Bone scaffold physical state and
composition
Hydrated chitosan-calcium phosphate
scaffolds
Hydrated CaP/polyurethane composites
Dry chitosan/β-TCP microspheres in
PMMA cement
Dry rapid prototyping-PCL scaffolds

Young’s modulus
(MPa)
9.29±0.8

Reference

2500-3600
400-1200

Yoshii et al.29
Lin et al.172

12.5 ± 2.3 in tension

Ahn et al.90

Dry porous sintered microsphere scaffolds
based on cellulose derivatives
Dry electrohydrodynamic –PCL scaffolds
Dry chitosan/HA nanocomposites in 50–50
ratio
Dry polygalacturonic acid/HA
nanocomposites in 50–50 ratio
Dry chitosan/HA/polygalacturonic acid
nanocomposites
Hydrated chitosan/collagen hydrogels

227±59—
292±40
6.3 ± 1.8 in tension
17560

Kumbar et al.121

29810

Verma et al.32

23620

Verma et al.32

0.0189

Wang et al.147

Chesnutt et al.40

Ahn et al.90
Verma et al.32

In vitro degradation studies were conducted on scaffolds to investigate the effect of
collagen on the degradation profile. At most 9.4±2.6% degradation of scaffolds was
observed in solutions without enzymes, whereas in solutions with enzymes, degradation
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was 2-2.5x greater (25.8±3.4%), indicating that enzymes would affect degradation.
Similar to the microparticles, it does not appear that composition had any affect, but it
does appear that the type of fusing acid did, with the glycolic acid-fused constructs having
greater mass loss than the acetic acid-fused scaffolds. The degradation is higher than that
of lysine-triisocyanate-based polyurethane-CaP (PUR) composites: PUR/HA-12% after 6
weeks and PUR/TCP-5% after 6 weeks,29 porous sintered microsphere scaffolds based on
cellulose derivatives-10–15% after 24 weeks.121 The degradation of scaffolds in the
control solution may be due to the following processes: dissolution of salts and simple
polymer hydrolysis. The two processes plus enzymatic hydrolysis of the polymers occur in
the lysozyme and collagenase solution, which almost tripled the mass loss. Jiang et al.
reported that chitosan-PLGA sintered microsphere-based scaffolds had ~0.5wt% loss,
three times lower than the 1.5wt% loss seen for PLGA sintered scaffolds after 12 weeks of
degradation.177 This shows the interaction between the polymers: the increase in chitosan
content decreases the degradation rate of the chitosan-collagen-based scaffolds. On the
contrary, the results of our study do not support any interaction between chitosan and
collagen polymers that can influence degradation.
In vitro cell viability studies on scaffolds were conducted to observe if there were
any cytotoxic effects with the increased calcium content and type of acid used for fusion
of scaffolds. In terms of cell attachment, osteoblasts grew more on chitosan
microparticles fused with acetic acid and 25% collagen microparticles fused with glycolic
acid than the other 4 groups (p<0.05). The cell attachment was lower than that of HEPM
cells on chitosan-HA-calcium phosphate scaffolds (>60% attachment after 2 h40 and
42.21±9.15%66), but this may be explained by the 10x higher initial cell seeding
concentration in the last two studies. The initial % of cells attached can be explained by
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the initial cell seeding concentration. The seeding concentration was 43.1 times lower
than for NIH-3T3 fibroblasts on beads. Additionally, the initial % of cells attached can be
explained by the fact that the pores of the scaffolds may have been filled with medium
before the pipetting of the cells, leaving cells to attach only to the surface of the scaffolds.
Moreover, two factors can explain the low cell attachment: the pull of gravity of cells
toward the bottom of the well where each scaffold lay and the propensity of cells toward
tissue culture plastic compared to the scaffold material. Shaking scaffolds of medium
before pipetting the cells may have increased the cell attachment, because cells would
have gone through the scaffold pores and spent more time, which meant more cells could
attach before being pulled by gravity toward the tissue culture plastic-bottom of the well.
LIVE/DEAD assay confirmed the presence of cells, although it wasn’t able to
show proliferation for all groups. In spite of osteoblasts growing on scaffolds, their low
initial seeding concentration (9.1 x 103 cells/mL) and the fact that the scaffolds weren’t
shaken to leave the pores free of medium before seeding with cells gave misleading
LIVE/DEAD images with low cell numbers (not presented). The cells didn’t completely
cover the scaffolds. All cells proliferated in time, as shown by CellTiter-Glo®, although
10% collagen beads fused with acetic acid showed a slight decrease in number on day 3,
but increased in number on day 7. The cells proliferated approximately 7x in a one-week
period. Looking at proliferation of osteoblasts or osteoblast-like cells on other bone
regeneration biomaterials, the proliferation of osteoblasts in the present study is better than
the average (higher than proliferation in 80% of the studies below), as it is higher than
scaffolds that contain CaP in the form of apatite or TCP, collagen, gelatin, chitosan29,40,9294,96,156

and smaller than the proliferation of scaffolds composed of chitosan, CaP in the

form of HA or PCL90,155 (Table 6).
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Table 6. Proliferation of osteoblasts or osteoblast-like cells on bone scaffolds.
Scaffold

Time

PLLA scaffolds coated with apatite

8 days

apatite-coated PLGA /HA scaffolds

day 7—day14

nanocomposite gelatin/10 and 30%HA

7 days

PLLA scaffolds coated with
apatite/collagen

8 days

polyurethane/HA

day 2— day 5

CMs (chitosan microspheres)/nHAC/PLLA
scaffolds

day 2— day 8

nHAC(nanohydroxyapatite/collagen)/PLLA day 2— day 8
SBF-treated HA-added microporous PCL
scaffolds
chitosan-calcium phosphate composite
scaffolds

day2—day30
7 days

polyurethane/TCP

day 2— day 5

chitosan scaffolds

day 1— day 6

chitosan-HA scaffolds

day 1— day 6

chitosan-HA-marine sponge collagen
scaffolds

day 1— day 6

control rapid prototyping-PCL scaffolds

3 days

Prolifera- Reference
tion (times
or fold)
Chen Y.
1.25
et al.92
Kim S.S.
1.3
et al.93
Kim
1.6 H.W. et
al.96
Chen Y.
1.75
et al.92
Yoshii et
2
al.29
Niu et
2.2
al.156
Niu et
2.5
al.156
Ciapetti
2.6
et al.94
Chesnutt
3
et al.40
Yoshii et
4
al.29
Pallela et
7
al.155
Pallela et
~11.5
al.155
Pallela et
~13.5
al.155
Ahn et
20
al.90

Collagen addition did not impact bead degradation and cell attachment and
proliferation, so χtosan-CaP, 10Coll-χtosan-CaP and 25Coll-χtosan-CaP are viable
microparticles for use as building blocks in bone grafts, ligaments or tissue fillers.
In order to determine which scaffold combination provides the best bone graft, cell
proliferation was considered as the primary factor in ranking scaffolds, Young’s modulus
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was the second factor and the degradation in PBS+enzymes was the third factor. Cell
attachment and porosity were considered as less important factors and are presented for
informative purposes, since cell proliferation is more important than attachment and cell
viability should explained by the porosity. Ranking of the scaffolds is presented in table 7.

Table 7. Ranking of the scaffolds based on top three factors. +++means best or
belongs to group 1 (as mentioned earlier) and + denotes the lowest outcome or belongs to
group 3.

Factors

χtosanCaPacet_ac

10CollχtosanCaP,
acet_ac

25CollχtosanCaP,
acet_ac

χtosanCaP,
glyc_ac

10CollχtosanCaP,
glyc_ac

25CollχtosanCaP,
glyc_ac

Cell
Proliferation

+++

+++

+++

++

+

++

Young’s
modulus

++

+

++

+

++

+

Degradation

+

+

+

++

++

+

Cell
attachment

++

+

+

++

++

++

Porosity

++

++

++

+

++

++

①

②

①

②

②

③

Ranking

In summary, chitosan-calcium phosphate and 25% collagen-chitosan-calcium
phosphate beads fused with acetic acid seem the most suitable bone graft. They are
followed by: χtosan-CaP, glyc_ac; 10Coll-χtosan-CaP, acet_ac, 10Coll-χtosan-CaP,
glyc_ac and lastly, by 10Coll-χtosan-CaP, glyc_ac. Thus, glycolic acid-fused beads
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performed worse as a potential bone graft, but all formulations show promise in bone
tissue engineering.
If any of the formulations for scaffolds have to be chosen for further research,
based on Young’s modulus, the best scaffolds would be the ones fused with acetic acid
and 10% collagen fused with glycolic acid. Based on degradation, the scaffolds fused with
glycolic acid degrade almost 2x as fast than the ones fused with acetic acid. Since cells
proliferate on all scaffolds and the number of cells that landed on the scaffold may differ,
the scaffolds may be considered similar in proliferation. Following this rationale, since
proliferation seems similar, the best scaffold in terms of degradation and stiffness would
be 10% collagen-calcium phosphate-chitosan microparticles fused with glycolic acid.
Lastly, it would be of interest to increase Young’s modulus to make the scaffolds loadbearing.
Furthermore, with the current mechanical properties and degradation profile, the
microparticles can serve as tissue fillers for craniofacial defects and should be tested in
vivo.
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CHAPTER 6: CONCLUSIONS
In this preliminary study, the design criteria were to improve the degradation of
previous chitosan-CaP microsphere-based scaffolds, perhaps improving cytocompatibility
and mechanical properties. To meet these design criteria, three composite microparticle
formulations with chitosan, calcium phosphate and variable percentages of collagen were
made by precipitation. These composite microspheres were evaluated in vitro for their
potential as bone tissue fillers. The microparticles were fused with either acetic or
glycolic acid and evaluated in vitro as potential bone scaffolds.
It was found that the microspheres with the target 10.0% and 25.0% collagen
incorporated only about 30% of the theoretical collagen. XRD analysis indicated that
chitosan and the crystalline form of calcium phosphate, HA, is present, as well as TCP.
All bead types degraded approximately 20% within 6 weeks, which predicts
degradation within 8 months, below the 13 month-remodeling phase and maturation of
bone.46 More NIH/3T3 fibroblasts than Saos-2 osteoblasts attached to the beads during
the 7-week culture period with no difference between microparticle types, which showed
good attachment, cytocompatibility and proliferation. Consequently, the data do not
support the hypothesis because the addition of collagen did not enhance degradation and
cytocompatibility of the microspheres. The proliferation was higher than in other
studies.97,175 Hence, all bead formulations (with and without collagen) may be used as
tissue fillers in craniofacial defects, osteoporosis or at the interface between bone and
ligament or bone and tendon, or potentially as ligament replacement (in a different shape,
of course).
The scaffolds were made from the three types of microparticles and fused with
two acids to evaluate differences in porosity, mechanical properties, cell attachment and
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proliferation. We demonstrated that, in spite of the overall decreased scaffold porosity
(~19-28%), the remaining pores were of adequate size for cell penetration. The at least
quadruple growth of osteoblasts on scaffolds stands as evidence for the biocompatible
properties of the composites. Glycolic acid-fused scaffolds exhibited lower Young’s
modulus except for 10% collagen than acetic acid-fused scaffolds (E~1 MPa) at 5%
strain. Young’s moduli for all scaffolds were about 10 times lower than the inferior limit
of the range of compressive elastic modulus reported for cancellous bone: 10-2000
MPa,43. All scaffolds, regardless of composition, displayed ~20% degradation in one
month, which prognosticated a 6-month dissolution. Moreover, all osteoblasts attached
and proliferated approximately 7x in a one-week period, which was higher than the
proliferation seen in several other studies.29,40,92-94,96,146,147,156,157
The addition of collagen to the microsphere-based scaffolds did not affect
degradation, cytocompatibility or Young’s modulus, which means that the hypothesis was
not supported. Collagen may not have had an effect due to the low collagen incorporation
(at most 7.6% collagen when compared to the mass of collagen and chitosan). In
conclusion, the collagen-chitosan-calcium phosphate scaffolds are promising candidates
for bone grafts that resorb and show good cytocompatibility.
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CHAPTER 7: FUTURE WORK
The results of this study showed about 30% incorporation of collagen in the
microspheres. One recommendation would be to look for ways of attaching collagen to
chitosan to favor higher retention. Another recommendation would be to use an
alternative base solution that will not degrade collagen.
The microparticles’ composition does not reflect the relative percentages of
components of native bone. Only collagen follows closely bone composition. Collagen is
19.8-20.1% of bone47 and 10% of adult bone mass is collagen,169 while we chose 10-25%
collagen. Another recommendation is to use a porous hydroxyapatite instead of calcium
phosphate and to increase its mass at the loss of chitosan to replace the mineral part of
bone (69% by mass)47 and provide higher Young’s modulus to make the scaffolds loadbearing.
Knowing that cancellous bone consists of 30% bone and 70% void volume, the
scaffolds should have about 30% porosity to allow for native bone ingrowth, while the
scaffolds degrade in time.176 The porosity of the collagen-chitosan-calcium phosphate
scaffolds can be increased by making the microparticles spherical. Spherical beads can be
obtained by lowering the dripping rate on the syringe pumps or by reducing the volume of
acid added to fuse the beads.
One approach to obtain higher cell attachment on scaffolds (if other cells, such as
mesenchymal stem cells are to be tested) is to seed scaffolds with a higher cell
concentration (in the range of 105 cells/mL). Shaking scaffolds of medium before
pipetting the cells may increase the cell attachment, because cells would spend more time
through the scaffold pores, which means more cells can attach before being pulled by
gravity toward the tissue culture plastic-bottom of the well where the scaffolds are kept.
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Additionally, the scaffolds can serve as anterior cruciate ligament, ACL,
replacement. For this purpose, the solution would have to be dried in strands that mimic
the anatomy of ligaments and tested in tension.
Moreover, different techniques (for example, HNO3) can be explored for fusing
these composite collagen-chitosan-calcium phosphate microspheres into 3D bone
scaffolds. It would be of interest to conduct a long-term degradation study on these
composite bone scaffold constructs fused by different techniques to evaluate their
mechanical integrity over the degradation time period. Likewise, of interest would be the
evaluation of the pattern of long-term cell growth on the composite collagen-chitosancalcium phosphate scaffolds in terms of bone cell morphology, gene expression and
mineralization markers, such as alkaline phosphatase, calcium content, collagen type I and
II, osteopontin, osteocalcin and bone sialoprotein.
The long-term ambition of this work is the implementation of at least one of these
types of microparticles and scaffolds as a medical device for use in the clinical setting.
Prior to that, the scaffolds should be evaluated for bone-forming properties for at least four
months in a Sprague-Dawley rat model. The microspheres can be inserted to fill a
calvarial defect, while the scaffolds can be inserted in a critical-sized defect in a rat femur.
Histology may be used to assess the ability of the biomaterials to aid in bone plerosis and
larger animals may be used prior to human assessment in clinical trials.
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APPENDIX A: DEGRADATION, CELL ATTACHMENT & GROWTH ON
MICROPARTICLES
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Figure 1. Degradation of microparticles in PBS + enzymes. Tukey’s test and one-way
ANOVA showed that all initial masses are statistically different (p<0.05). Regression
analysis showed that the degradation rates are similar (α=0.05). n=4

Table 1. Regression lines of the degradation of microparticles in PBS + enzymes. There
is no statistically significant difference in slope or degradation rate between groups.
Groups
χtosan-CaP
10Coll-χtosan-CaP
25Coll-χtosan-CaP

R2
0.3820
0.5217
0.6888

Regression lines
Y=0.2965x+6.4989
Y=0.3336x+5.9993
Y=0.4094x+2.5201
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Figure 2. Degradation of microparticles in PBS (control). One-way ANOVA and
Tukey’s test showed that all initial masses are statistically different (p<0.05). The beads
showed a loss of mass over time. Regression analysis163 showed there were no
differences in the degradation rate (p<0.05). n=4

Table 2. Regression lines of the degradation of microparticles in PBS. There is no
statistically significant difference in slope or degradation rate between groups.
Groups
χtosan-CaP
10Coll-χtosan-CaP
25Coll-χtosan-CaP

R2
5E-5
0.1446
0.0285

Regression lines
Y=-0.0024x+6.0286
Y=0.1332x+5.0050
Y=0.0664x+2.7645

Table 3. Cell attachment on microparticles.
Cell attachment (%)
Microparticles

χtosan-CaP

10Coll-χtosan-CaP

25Coll-χtosan-CaP

fibroblasts

40.6±8.0

38.5±6.8

43.2±8.7

osteoblasts

27.3±13.1

22.5±6.0

27.6±4.8
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The results of the proliferation study are summarized in table 4.
Table 4. Cell proliferation on microparticles on the last day of proliferation
# cells/microparticle
Microparticle
s

χtosan-CaP

10Coll-χtosan-CaP

25Coll-χtosan-CaP

fibroblasts

5744±1343

6324±792

5536±1077

osteoblasts

4965±1459

4910±359

5579±1173

Table 5. Regression lines of fibroblasts’ proliferation on microparticles. There is no
statistically significant difference in slope or proliferation rate between groups.
Groups
χtosan-CaP
10Coll-χtosan-CaP
25Coll-χtosan-CaP

R2
0.8691
0.9717
0.8844

Regression lines
Y=787.34x+170.04
Y=846.47x+443.64
Y=681.86 x+840.84
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Figure 3. Regression for fibroblasts’ proliferation of microparticles. There is no
statistically significant difference in the proliferation rate (α=0.05).

χtosan

10Coll-χtosan-CaP

25Coll-χtosan-CaP

Day 3

Day 7

Figure 4. Fibroblasts’ viability on microparticles.
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χtosan

10Coll-χtosan-CaP
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Day 7

Figure 5. Osteoblasts’ viability on microparticles.
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APPENDIX B: YOUNG’S MODULUS, DEGRADATION AND VIABILITY OF
OSTEOBLASTS ON SCAFFOLDS
1.6

*

p=0.005

Young's modulus (MPa)

1.4
1.2

*

*

*

χtosan-CaP, acet_ac
10Coll-χtosan-CaP, acet_ac

1

25Coll-χtosan-CaP, acet_ac

0.8

χtosan-CaP, glyc_ac
0.6

10Coll-χtosan-CaP, glyc_ac

0.4

25Coll-χtosan-CaP, glyc_ac

0.2
0

at ε=0.01

Figure 6. Young’s modulus in compression of composite scaffolds for ε=0.1 (n=10).
Acet_ac: acetic acid; glyc_ac: glycolic acid. Two-way ANOVA showed that all three
types of microparticles fused acetic acid differ from those fused with glycolic acid. Error
bars are standard deviations. *=difference between groups (p<0.001).

Table 6. Regression lines of the degradation of scaffolds in PBS +enzymes.
Groups

R2

Regression lines

1=χtosan-CaP, acet_ac
2=χtosan-CaP, glyc_ac
3=10Coll-χtosan-CaP, acet_ac
4=10Coll-χtosan-CaP, glyc_ac
5=25Coll-χtosan-CaP, acet_ac
6=25Coll-χtosan-CaP, glyc_ac

0.9302
0.8822
0.6220
0.8648
0.6453
0.6478

Y=4.0960 x-4.9639
Y=6.5865x-1.9860
Y=3.4877 x-2.2552
Y=6.4632x-0.9183
Y=4.4350 x+2.9949
Y=4.7718x+6.0838
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Statistical
significance in slope
1 vs. 2 (p<0.05)
1 vs. 4 (p<0.05)
2 vs. 3 (p<0.05)
3 vs. 4 (p<0.05)

30

25

χtosan-CaP, acet_ ac
χtosan-CaP, glyc_ ac

%Δmassscaffolds

20

10Coll-χtosan-CaP,
acet_ ac
15

10Coll-χtosan-CaP, glyc_
ac
25Coll-χtosan-CaP,
acet_ ac

10

25Coll-χtosan-CaP,
glyc_ac
5

0
0
-5

1

2

3

4

5

Time

Figure 7. Degradation of scaffolds fused with acetic vs. glycolic acid in PBS + enzymes.
N=4

Table 7. Regression lines of the degradation of scaffolds in PBS.
Groups

R2

Regression lines

1=χtosan-CaP, acet_ac
2=χtosan-CaP, glyc_ac
3=10Coll-χtosan-CaP, acet_ac
4=10Coll-χtosan-CaP, glyc_ac
5=25Coll-χtosan-CaP, acet_ac
6=25Coll-χtosan-CaP, glyc_ac

0.8857
0.6407
0.5933
0.6851
0.0599
0.1757

Y=2.0398x-6.0857
Y=2.1123x-3.5685
Y=2.3998x-5.7657
Y=2.4057x-2.7063
Y=0.6124x+0.9824
Y=1.4450x-0.3592
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Statistical
significance in slope
1 vs. 5 (p<0.05)
3 vs. 5 (p<0.05)
4 vs. 5 (p<0.05)
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6

χtosan-CaP, acet_ ac

%Δmassscaffolds

4
χtosan-CaP, glyc_ ac

2

0
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1
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acet_ ac
25Coll-χtosan-CaP,
glyc_ac

-2

-4

Time (weeks)
-6

Figure 8. Degradation of scaffolds fused with acetic vs. glycolic acid in PBS. N=4

Table 8. Regression lines of the osteoblasts’ proliferation on scaffolds.
Groups

R2

Regression lines

1=χtosan-CaP, acet_ac
2=χtosan-CaP, glyc_ac
3=10Coll-χtosan-CaP, acet_ac
4=10Coll-χtosan-CaP, glyc_ac
5=25Coll-χtosan-CaP, acet_ac
6=25Coll-χtosan-CaP, glyc_ac

0.6633
0.5644
0.6481
0.4018
0.5162
0.5910

Y=1670.2x-913.08
Y=1219 x-370.6
Y=1474.7 x-654.68
Y=574.48 x+1802.4
Y=2410.5 x-1033.4
Y=1493.8 x+779.79
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Statistical
significance in slope
1 vs. 4 (p<0.05)
3 vs. 4 (p<0.05)
4 vs. 5 (p<0.05)
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Figure 9. Regression analysis of osteoblasts’ proliferation on scaffolds.
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Figure 10. Osteoblasts’ viability on scaffolds fused with acetic acid.
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Figure 11. Osteoblasts’ viability on scaffolds fused with glycolic acid.
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